The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris

In this episode, my guest is Robin Carhart-Harris, PhD, distinguished professor of neurology and psychiatry at the University of California, San Francisco. He is one of leading researchers in the study of how psychedelics such as psilocybin, LSD and DMT can change the human brain and in doing so, be used to successfully treat various mental health challenges such as major depression, anorexia, obsessive-compulsive disorder (OCD) and addiction. He explains how psilocybin induces sustained changes in adaptive brain wiring and cognition. We discuss the key components of safe and effective psychedelic journeys, the role of hallucinations, the use of eye-masks to encourage people to “go internal,” and music, as well as what effective therapist support consists of before, during and after the session (also known as integration). We discuss micodosing vs. macrodosing and how researchers control for placebo effects in psychedelic research. We also discuss the current legal landscape around psychedelic therapies. Psychedelic therapies are fast emerging as powerful and soon-to-be mainstream treatments for medical health disorders, but they are not without their risks. As such, this episode ought to be of use to anyone interested in brain plasticity, mental health, psychology or neuroscience. For the full show notes, visit hubermanlab.com. Thank you to our sponsors AG1: https://athleticgreens.com/huberman LMNT: https://drinklmnt.com/hubermanlab Waking Up: https://wakingup.com/huberman Momentous: https://livemomentous.com/huberman Timestamps (00:00:00) Dr. Robin Carhart-Harris (00:02:28) Sponsors: LMNT & Waking Up (00:05:41) The Brain-Body Contract (00:06:31) Origin of the Word: “Psychedelics”; Pharmacology (00:12:05) Psychedelics & Revealing the Unconscious Mind, Psychotherapy (00:17:32) Microdosing (00:26:08) Psilocybin vs. Magic Mushroom Doses (00:28:28) “Psychedelic-Therapy”, Music (00:31:13) Sponsor: AG1 (00:36:26) Psychedelic Journey: “Trust, Let Go, Be Open” (00:43:01) Negative Emotions, Fear & Psychedelics (00:46:21) Global Functional Connectivity, Serotonin 2A Receptor; Subjective Experiences (00:52:33) Pharmacology: Therapeutics without Psychedelic Effects; SSRIs (00:58:45) Psilocybin & Depression; Long-Term Effects: Connectivity & Neuroplasticity (01:10:26) Psilocybin Therapy & Anorexia (01:12:56) Integration Phase & Psychedelic-Therapy; Meditation (01:19:50) First-Time Psychedelic Use, “Entropic Brain Effect”, Neuroplasticity, Cognition (01:30:16) Fibromyalgia & Psychedelic Treatment; MDMA Therapy & “Inner Healer” (01:38:55) Placebo Response & Psychedelic Therapy (01:41:39) LSD & Psychedelic-Therapy, Micro-Dose (01:48:19) Combination Psilocybin-MDMA Therapy (01:56:06) DMT “Rocketship” & Serotonin 2A Receptors; Ibogaine (02:01:04) “Ego Dissolution”, Cocaine vs. Psychedelics; Relapses (02:12:26) Psychedelics & Legal Landscape; Decriminalization (02:17:54) MDMA, Trauma & Clinical Trials; Future Regulatory (FDA) Approval? (02:23:25) Psilocybin & Current Clinical Trials (02:28:41) Mental Health & Psychedelic Treatment, Safeguards, Paradigm Shift (02:34:39) Zero-Cost Support, YouTube Feedback, Spotify & Apple Reviews, Sponsors, Momentous, Social Media, Neural Network Newsletter Disclaimer Learn more about your ad choices. Visit megaphone.fm/adchoices

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:00Andrew D. Huberman?

  Welcome to the Huberman Lab Podcast, where we discuss science and science-based tools for everyday life.

• 0:09Andrew D. Huberman?

  I'm Andrew Huberman, and I'm a professor of neurobiology and ophthalmology at Stanford School of Medicine. Today, my guest is Dr. Robin Carhart-Harris. Dr. Carhart-Harris is a distinguished professor of neurology and psychiatry at the University of California, San Francisco. He is one of the leading researchers in the field of psychedelics and how they change neural circuitry in the brain. His laboratory is responsible for understanding, for instance, how psilocybin, also sometimes referred to as magic mushrooms, change neural circuitry in the brain such that new ideas and new forms of learning occur. His laboratory is also responsible for carrying out various clinical trials, some of which have demonstrated that appropriate dosages of psilocybin can alleviate major depression

• 0:51Andrew D. Huberman?

  in more than 67% of people that take the drug. Now, this is not to say that everybody should take psilocybin. And today's discussion describes both the clinical trials and why treatments with psychedelics in some cases work and in some cases do not work in order to treat major depression, as well as discussions around psilocybin, lisergic acid, diethylamide, sometimes also referred to as LSD, as well as DMT, and how these change the brain and how those brain changes can relate to changes in mental health as it relates to depression and other psychiatric challenges, as well as how psychedelics are being applied in order to change neural circuitry for sake of expanding different aspects of the human mind, including creativity, intelligence, and much more. During today's discussion, Dr.

• 1:35Andrew D. Huberman?

  Carhart-Harris teaches us about the history of the study of psychedelics, as well as how the legislature, that is, the laws surrounding psychedelics, are evolving in the United States and elsewhere for the use of psychedelics to treat psychiatric challenges. By the end of today's discussion, you will have a thorough understanding of how psychedelics work. Both in the short term during the actual journey or trip, in fact, much of my discussion today with Dr. Carhart-Harris talks about the different aspects of the psychedelic journey and how those relate to therapeutic outcomes. And of course, by the end of today's discussion, you will also understand the long-term effects of psychedelics. That is, how they can actually rewire the brain. Before we begin, I'd like to emphasize that this podcast is separate from my teaching and research roles at Stanford. It is, however, part of

• 2:18Andrew D. Huberman?

  my desire and effort to bring zero cost to consumer information about science and science-related tools to the general public. In keeping with that theme, I'd like to thank the sponsors of today's podcast.

• 2:28Speaker 01

  Mr. President, my company told me of the explosion on our rig on October 2nd. Causing massive water displacement and triggering a tsunami. They all keep the blame on me.

• 2:37Speaker 02

  Tom Cruise is. Digger got us into this mess. And Digger's gonna dig us out. From the director of Birdman and the Revenant.

• 2:45Speaker 03

  What would happen if I stopped drilling? You're stalled, you're freezing there, that's what.

• 2:49Speaker 02

  With great power comes great deniability.

• 2:52Speaker 03

  I'm not the first then.

• 2:53Speaker 02

  Digger. See the trailer online. Only in theaters October 2nd. Rated R. Under 17 and under 18 without parent.

• 3:01Speaker 04

  You could try to find the perfect coffee to water ratio, or you could press a button. With Keurig, each K-Cup pod is precision measured for a perfectly delicious cup. No effort, no grind, no math required. Great coffee without the grind. Keurig.

• 3:23Andrew D. Huberman?

  And now for my discussion with Dr. Robin Carhart-Harris. Dr. Carhart-Harris, welcome. I've been wanting to talk to you for a long time. I certainly have known who you are for quite a while because I place you in this very small, but very special and important category of researchers who has been pioneering the use of psychedelics for the treatment of specific clinical conditions and really carrying the torch for essentially the entire field. So I want to start with a voice of gratitude and say thank you for doing this incredibly important work. Could you tell us a little bit about what psychedelics are? In fact, I'm curious as to how the name psychedelic ever came to be and what you

• 4:08Andrew D. Huberman?

  think they potentially reveal about the workings of the brain. And then we'll talk about the clinical applications. Sure. Well,

• 4:17Speaker 05

  Even that one is a kind of hot one because opinions differ on how to define psychedelic. But perhaps a good starting place is to start with the etymology, where did the word come from? And it was a Brit, excommunicated, living in Canada, Humphrey Osmond, who was due to present a paper at a National Academy of Sciences meeting on psychotomimetics, drugs that mimic aspects of psychosis in their action.

• 4:56Speaker 05

  And certain drugs like mescaline, let's see, 1956, and LSD were on the bill. And he felt dissatisfied with them being under this category of psychotomimetics and felt that the signature psychological effects of these compounds went beyond just mimicking psychotic symptoms. And so he wanted to find a more apt term to speak to, in a sense, the principal component of their action. And he jotted down a few different possibilities, about a dozen or so, I think. And one of them was psychedelic, actually, it started as and ended up being psychedelic.

• 5:41Speaker 05

  And he had a correspondence going on with another Brit, also living in the US, Aldous Huxley, where they were playing with some terms to refer to these compounds. And in the end, Osmond won with psychedelic and he had this little ditty of, "To fathom hell or saw angelic, just take a pinch of psychedelic."

• 6:11Speaker 05

  That's where you put the disclaimer. And so what does that mean? It's to ancient Greek word psyche means the human mind. Or if we're being actually true to the ancient Greek, it means soul. And then the other component means to make clear or to make visible or to make manifest or to reveal. So all of those work. And it's it's a neologism. It's a made up word, but it does have that ancient Greek origin.

• 6:49Speaker 05

  And it's speaking to this principle that these compounds reveal aspects of the psyche, of the human mind, the soul, that are ordinarily not entirely visible. And so that's the etymology and it's wonderfully poetic, but I happen to think it's also very accurate. It's a useful term because it's sort of, you might say, valence nonspecific. It doesn't say you're going to have a great time or that you're going to go mad. It's more that it reveals psyche and it could be hellish, but it could be heavenly.

• 7:29Speaker 05

  And so that's the etymology and also a bit of the psychology and sort of, you know, pointing to the phenomenology, the subjective experience. But there's also a pharmacology here. And quite recently, there was put out a consensus statement about psychedelics that's really referring to what we call the classic psychedelics, to say that these are all compounds that work on a particular receptor in the brain, the serotonin 2A receptor. And that's another way that we could define these compounds. I said this one's a little hot because I'm of the view that while the pharmacology is

• 8:13Speaker 05

  really useful, how the drugs work chemically, you can't avoid the phenomenology. And if we're true to the etymology, where the term came from, then we must recognize and we cannot neglect the subject of experience.

• 8:30Andrew D. Huberman?

  Thank you for that beautiful description of what brought us to today in terms of using the word psychedelics, and now it's thrown around all the time.

• 8:39Speaker 05

  Yeah, too much.

• 8:40Andrew D. Huberman?

  Yeah, too much, and I'm guessing, well, not guessing, I'm certain that it's also used to describe many compounds that don't touch the 5HT2A, the serotonin 2A receptor. So there is a broader categorization by most people, and it'll be interesting to see where all the nomenclature and naming goes. For the time being, I'd love for you to tell us a bit more about this idea that psychedelics, however one defines them, can reveal something about the mind that can't be revealed otherwise. Are you talking about the subconscious? I mean, psychologists, and most famously Freud, but also Jung, and also neuroscientists, I think, think about subconscious processing.

• 9:25Andrew D. Huberman?

  I think perhaps the most salient example for me that's outside the realm of anything psychedelic would be blindsight, this phenomenon that you take people that are blind but still have some connectivity in their brain, and you present them a board with, or a computer screen with different number of dots on each side, and you say, "How many dots are on each side of the screen?" And they say, "What do you mean? I can't see the screen, I'm blind." And you say, "Well, just guess." And their guess rate is accurate far more than chance would predict. So they have so-called blindsight, and people have said, "Well, this is the subconscious revealing itself." There's no psychedelic drug involved, but what you're describing is a pharmacologic-induced

• 10:08Andrew D. Huberman?

  state that reveals something that normally, should we assume, is masked, or that we are oblivious to even though it's expressing itself? What does it mean for these drugs to be revealing something about the workings of the mind that would not be obvious to us otherwise?

• 10:28Speaker 05

  Yeah. So the example of blindsight is interesting, but it's different. Blindsight would be referring to non-conscious processing, maybe implicit processing, so stuff going on in the mind in perception, in a sense, that is below the threshold of conscious awareness, but yet is influencing you. So it's sort of, it's kind of related, but it's different. So in-depth psychology, psychoanalysis, psychodynamic psychology, you know...

• 10:59Speaker 05

  Sigmund Freud, Carl Jung, and so on. We talk about the unconscious. And there, it's more about the kind of blood and guts of the human condition, the human nature, both the personal unconscious, so things that you might not want to necessarily be conscious of because it's painful. So that's the repression aspect, pushing it out of conscious awareness.

• 11:27Andrew D. Huberman?

  Repressed memories in particular?

• 11:29Speaker 05

  Yeah, like traumatic memories, difficult relationships. It could be complex trauma, not necessarily just a specific, you know, index trauma, but a series of trauma. And then you have the collective unconscious, which was really Carl Jung's contribution to say that, you know, there's a transpersonal quality to the unconscious. There's aspects about humans, not just this individual human. There's aspects to our minds, our psyches, that are not fully available to conscious awareness, but can come up in certain states. You know, psychoanalysis went crazy for dreaming

• 12:13Speaker 05

  as their royal road to a knowledge of the unconscious. That was Freud. But we now know with psychedelics, and this was what drew me into the area, was discovering literature that was speaking to this particular action, the psychedelic action. And was saying that when these drugs, like LSD, psilocybin, found in magic mushrooms, when they're used in psychotherapy, material comes up that maybe may have been repressed, that is of, you know, therapeutic value.

• 12:58Speaker 05

  And awareness and insight of this material seems to catalyze the therapeutic process with, you know, strong emotional release, these cathartic experiences and insights, you know, whether they're insights that are personal or whether they're transpersonal.

• 13:18Speaker 05

  But for me, this is really where the meat of it is with psychedelics and classic psychedelics in particular, the likes of compounds like LSD and psilocybin. I would say that if it wasn't for this action by classic psychedelics, we wouldn't be so interested in psychedelics. I think if we only had compounds like ketamine, MDMA, cannabis, that could be said broadly speaking to be psychedelic-like, I don't think it necessarily would have captured the world's attention as psychedelics are right now.

• 13:57Speaker 05

  I actually think it's a major gap to fill is this principal action of the classic psychedelics. What does this mean that I'm referring to psyche revealing? What is that? And I suppose where I'm going with this is what is that in terms of the biology as well? What's going on in the brain and the body when people become aware of things that previously they weren't fully aware of?

• 14:28Andrew D. Huberman?

  I'd like to talk about some of the clinical trials that you've been involved with, in particular, looking at psilocybin, as you mentioned, the principal hallucinatory psychedelic agent in magic mushrooms. I'd like to start with a kind of nuts and bolts question, just so that everyone's on the same page. I've read the papers that you've published and that others have published in this area. And typically, the dosages used in these trials are 25mg of psilocybin. And we talk about one recent trial in particular that compared 25 to 10mg to more frequent use of very small amounts, 1mg over three weeks, for instance. However,

• 15:14Andrew D. Huberman?

  When people talk about magic mushrooms, they often talk about gram doses of the mushroom, because I'm assuming that they contain milligram dosages of psilocybin. Here, we're not encouraging use of any kind. These are clinical trials. But for clarity of understanding, what is the conversion typically? Like, one gram of magic mushrooms will contain how many milligrams of psilocybin on average? Because what I'm trying to do here is calibrate people to this idea of microdosing versus macrodosing. And that's fairly straightforward to do with respect to the clinical trials. But then, in the... A lot of the lay discussion around this,

• 15:57Andrew D. Huberman?

  you hear about heroic doses versus microdoses. And so I think there's a lot of confusion. So if you would,

• 16:06Andrew D. Huberman?

  educate us on this idea of what's a microdose? And perhaps also, how many milligrams of psilocybin are contained in a gram of "magic mushrooms"?

• 16:18Speaker 05

  Sure. Well, a microdose is... Neither of these are that simple, but they're fun. It's a fun challenge. But microdose, one definition is that it's a dose of typically a classic psychedelic, like LSD or psilocybin, that is... that has sub perceptible psychedelic effects. Like, it doesn't put you into a noticeable altered state of consciousness that feels like you're tripping.

• 16:51Speaker 05

  And if that was LSD, it looks as though the threshold is around about, let's see, 10, 11, 12 micrograms?

• 17:02Andrew D. Huberman?

  Micrograms.

• 17:02Speaker 05

  Micrograms.

• 17:03Andrew D. Huberman?

  Want to be very clear here. Micrograms. So 10... So 10 micrograms of LSD, are you saying, will not induce visual hallucinations in most people?

• 17:13Speaker 05

  So it's... That's threshold level. That's about the level that some people who are sensitive could feel it. But if you were to talk to the microdosing gurus, they might say that that's kind of the ballpark for an LSD dose that you would consider a microdose, and then you would take sort of semi-regularly. It's typically something like one day on, one day off, or... One day on, two days off, this kind of thing. There's different protocols. And um yeah, so you know, some like Jim Fademan, um uh one of the popularizers of microdosing.

• 17:56Speaker 05

  I think would say that a true microdose should be sub perceptible. You shouldn't feel it, yet the assumption is it's going to change you in some way. Uh on a kind of trait level, more than a state level. Um and maybe behaviorally. Um and the typical story goes, it will improve well being. And maybe, maybe it could improve certain aspects of cognition, say, related to creative thinking. Um I emphasize the maybe there because that's another angle with microdosing. We're kind of waiting for some compelling evidence. As things stand right now, I'd say we lack uh that compelling evidence.

• 18:40Speaker 05

  There's some suggestive stuff, but often the study designs aren't that strong. It's really hard to do a study with microdosing because you need to have permission to give people a microdose that, you know, for practical reasons, they would go home with. And um otherwise, you you're requiring them to be in the lab, say, three times a week for X number of weeks to meet the criteria of a course of microdosing, which might be, you know, two or three times a week for, say, a month. And that's a hard thing to do in a lab study. It's expensive.

• 19:23Speaker 05

  You'd need to do that against a suitable control, so a placebo control. And there is a study that's been done in New Zealand um that has some interesting preliminary data that did, I think, kind of did the design right. Um. But it hasn't been published yet. I've seen some positive findings presented around improvements in mood, but it's a bit early to get too excited about that. Needs to go through peer review and all that. But as things stand, you know, the evidence is pretty thin. And, and, you know, we have to be honest about that.

• 20:06Speaker 05

  We did quite a creative study with my colleagues at Imperial. The guy leading that, Balas Shigeti, Hungarian chap, did a really creative design, very much his brainchild. He instructed people to do their own blinding, their own placebo-controlled blinding of their own microdosing. So this was a classic citizen science study, like do-it-yourself science, where they would get their LSD tabs and chop them up, put them into gel capsules, opaque, and have other capsules that are the placebos that they just close, empty capsule. And then there was a whole barcode scan technique

• 20:49Speaker 05

  so that you, you kind of shuffle them up, you know, but they've got the barcode in, the QR code. So you can break the code later on, but once you've shuffled them up, you no longer know which ones have the, the microdosing and which ones are empty. Was this LSD? This was LSD. He also tried it with mushrooms, but the issues with the mushrooms was people would burp sometimes. They'd belch and then they'd have this mushroom taste. So then he instructed people to get some like non-psychoactive mushroom material to put in. So it's really- Not an easy study. Not an easy study. And, and it was, I love that kind of science, you know, real creative, first mover kind of science.

• 21:33Speaker 05

  And the results are fascinating because the short story is that the microdosing didn't compellingly beat the placebo. It did not. It didn't. And he controlled, because he asked, he controlled for expectancy. So people's positive expectancy, which is in a sense the vehicle that carries the placebo response. It's why you have a placebo, is that positive expectancy can drive a therapeutic effect to, you know, a large extent. So he measured that pre-trial and then used it to kind of correct for the response. And how did it work?

• 22:12Speaker 05

  Those who got a placebo but thought they got a microdose did as well as those who thought they got a microdose and did get a microdose. So it was the bigger effect, the majority of the effect was in thinking that you got a microdose. So in a sense, it was a victory for the power of the placebo response. And it's created all sorts of controversy. People don't want to believe it, you know, that kind of thing. But that's the beauty of science, isn't it? That science is not about what you want to believe. That right there is the beauty of science, really.

• 22:50Andrew D. Huberman?

  I love that experiment. Kudos to them. I'm not going to attempt to say his last name correctly.

• 22:57Speaker 05

  I tried, yeah. Probably made a mess of it.

• 22:59Andrew D. Huberman?

  No, no, I think you got it. You were involved in a clinical trial that was published last year comparing 25mg of psilocybin to 10mg of psilocybin. It's a very, to a drug called eskitalopram?

• 23:20Speaker 05

  Yeah, Lexapro, yeah.

• 23:21Andrew D. Huberman?

  Lexapro. And it's one milligram over a three-week dosage. In wanting to discuss the results of that study a bit and some of the other trials that you've done involving psilocybin for depression, the treatment of depression. Could we calibrate ourselves? 25mg of psilocybin is, is that what wouldn't, it's going to be a perceptible dose presumably? Hallucinations and all that? And is that what one would find in, I'm guessing here, if I'm accurate, this does not mean that I have experience here, but two, two grams of mushrooms?

• 23:56Speaker 05

  More than that, we think, yeah. Sorry, I missed that, missed that one. Went off on a tangent. But yeah, 25mg of psilocybin would be, we don't know. And, and it's important that I say that because I wouldn't want people to hear my answer here and then use it to calibrate their own dosing of mushrooms and get it way off. So it's guesswork and I would love to see someone do a proper study on it and, you know, look at the psilocybin content in a given mass of.

• 24:31Speaker 05

  Psilocybe mushrooms, magic mushrooms. But to my knowledge, that hasn't really been done.

• 24:38Speaker 05

  Someone like Paul Stamets would would give a better answer here. But I think the percentage within the mushroom mass is some of psilocybin in the mushroom mass. And psilocin, which is a metabolite of psilocybin, is something in the 1%, a little bit higher maybe, range.

• 25:00Andrew D. Huberman?

  Okay, so 1, 1 gram, 1,000 milligrams of magic mushroom would contain about 10 milligrams of psilocybin, is that right?

• 25:10Speaker 05

  Broadly speaking, yeah.

• 25:11Andrew D. Huberman?

  Great, that helps calibrate. And I think, again, just allows the layperson to understand a bit more of where we're headed with these psilocybin trials and the results. So we don't have to restrict our discussion to just that one clinical trial. But if we include that one and compare to some of the other trials that you've done. I mean, your laboratory is seeing phenomenal, in my opinion, phenomenal results in the treatment of otherwise intractable depression, major depression, which so many people suffer from, from two, I suppose there are two sessions of using psilocybin in these ranges of 10 to 25 milligrams. Do I have that correct?

• 25:56Speaker 05

  Yes.

• 25:57Andrew D. Huberman?

  Okay, could we talk a little bit about what people typically experience during those sessions that allows this phenomenal transformation of mood and state and trait as well? And I'm especially interested in whether or not it is the experience during those sessions that is the trigger that's necessary for the the transformation from a depressed to a non-depressed state. Because the the impulse is to think it is, that what one thinks and sees and hallucinates is and hears is so vital. But of course, these drugs can create neuroplasticity, changes in our neural wiring, presumably for long periods of time.

• 26:41Andrew D. Huberman?

  So what are your thoughts on the the experience itself? And maybe for those who have not done these compounds before, you could explain a little bit about what's typical for people and what you think is leading to that incredible positive and pervasive change in mood, state and trait?

• 26:58Speaker 05

  I would, I would say that it's more than impulse that is leading us to think that the experience is important. It's really data and, and converging evidence now. So independent teams, independent studies are converging on the magnitude of certain kinds of experience rated, yes, with subjective rating scales is predicting therapeutic outcomes pretty, pretty strongly and very reliably. And so that's guiding us. Now, could you say, well, maybe those experiences are some kind of epiphenomenon of, say, a central brain action? Well, absolutely. But then all experience is an epiphenomenon by that

• 27:43Speaker 05

  principle. And yet we care about it, you know? And it matters to us and in our human relations with each other. So I think it does matter to a human being when they're in a, say, a psilocybin therapy session. And as the drug effects begin to come on and their body starts to feel a little strange and tingly. And there's some initial anxiety. And then in their mind's eye, they start to notice patterns and maybe colors. And then maybe those patterns deepen and they're dynamic. And they have this fascinating organic quality.

• 28:25Andrew D. Huberman?

  Are the patients in your studies typically using a, an eye mask?

• 28:30Speaker 05

  Yeah.

• 28:31Andrew D. Huberman?

  So they're in the eye mask, so eyes closed?

• 28:32Speaker 05

  Yeah.

• 28:33Andrew D. Huberman?

  That's why you said mind's eye as opposed to looking out into the clinical setting?

• 28:37Speaker 05

  Yes. And that's one of the major differences to psychedelic therapy versus taking a psychedelic is you shut your eyes, you know? And it's a, it's a world away from taking a psychedelic, yeah, a rave or something, you know? In a sense, good luck with that. But in psychedelic therapy, yeah, it's, it's, you know, settled conditions. There's music playing. And what I'm describing here is very much the default. There's, there's actually

• 29:07Speaker 05

  You know, very little variability between the different sites that have done this work on these conditions. Typically, it's two people. Ideally, mental health professionals, at least one who's a psychiatrist or a clinical psychologist or some other kind of psychotherapist or psychiatric nurse.

• 29:29Speaker 05

  But ideally, two who meet those criteria with an individual who's ingested the drug and music playing throughout a kind of runway into taking the drug and then throughout. So there's continuity.

• 29:44Andrew D. Huberman?

  Music with lyrics or without lyrics?

• 29:47Speaker 05

  Without lyrics to begin with and the music typically is spacious to begin with.

• 29:55Speaker 05

  And then builds and becomes atmospheric.

• 30:01Speaker 05

  There might be, I don't know, some tribal drums in the distance or something as it develops. Or like the sound of a bird in the distance, you know, a bird's call.

• 30:13Speaker 05

  And then as it gets into more stronger drug effects, the music starts to coax emotion. And very intentionally, you know, strings, for example, would come in. And it would be an interesting experiment and one that we'd love to do, actually, to see whether if you were to pull that out, whether the psychedelic experience would be as emotionally intense as it is in psychedelic therapy when you have music there as a default. And across the board, people should find this remarkable because it kind of is. All of the published studies that are now.

• 30:58Speaker 05

  You know, having such an impact on psychiatry and beyond, have music there as a staple component. And we just take it as assumption that it needs to be. I tend to share that assumption, but it's remarkable that it hasn't been tested properly. But it's there. And, you know, if you were to run with that, and if you were, you know, had a kind of critical agenda, you would say, well, this is music therapy, you know? Why are you making all this fuss about psychedelics? Where it's music that's there in all of these trials with all these fantastic findings. So there is something to that, you know?

• 31:38Speaker 05

  And this will tee me up probably to talk about psychedelic therapy being a combination treatment. We have a hyphen between the two because I share the hypothesis, the assumption that should be tested better, that there is a positive interaction between the two, that there's a synergy between the two. That's why it's psychedelic therapy with a hyphen. Just like Cart Hart Harris.

• 32:05Speaker 01

  Mr. President, my company tore me of the explosion on our rig on October 2nd. Causing massive water displacement and triggering a tsunami. They all keep the blame on me. Tom Cruise is.

• 32:18Speaker 02

  Digger got us into this mess, and Digger's gonna dig us up. From the director of Birdman and The Revenant.

• 32:24Speaker 03

  What would happen if I stopped going? You start, you freeze in there, that's what.

• 32:28Speaker 02

  With great power comes great deniability.

• 32:31Speaker 03

  I'm not the first then.

• 32:33Speaker 02

  Digger, see the trailer online, only in theaters October 2nd. Rated R, under 17, not a minute without parent.

• 32:38Andrew D. Huberman?

  This is extremely useful to hear because I think most people think, okay, psychedelic, whether or not they have experience with psychedelics or not, get some visual hallucinations, some auditory hallucinations, some synesthesia, some visual auditory blending, somatosensation, you know, rubbing a surface and being able to elicit the sounds in one's mind, of course, et cetera. But so seldom do we actually hear about the specifics of these clinical trials in a way that, for instance, points to music as one of the perhaps key variables. Now, you mentioned that as people enter these psychedelic states, that there's a little bit of initial anxiety.

• 33:19Andrew D. Huberman?

  About a year and a half ago, I had a discussion with Dr. Matthew Johnson, who's running some psilocybin trials at Johns Hopkins, as you know. And he mentioned the critical importance, at least in his mind, to this idea of the patient, quote unquote, "letting go" or allowing the experience to take them someplace mentally, as opposed to trying to constrain their sensory and cognitive experience. I'm curious what your reflections are on that idea and why it might be so valuable clinically. And this ties back to this earlier discussion we were having

• 34:02Andrew D. Huberman?

  about the unconscious or about psychedelics revealing something that's there all the time, but that we don't have access to. You know, and again, I'm struggling to find the right language for this because we don't really have a neural mechanism, like, you know, top-down inhibition or something like that, to explain how this, you know, unconscious might be uncorked in the psychedelic experience. But to make it quite simple and direct, how important do you think it really is for the patient to feel like they are, quote unquote, "letting go"? And what in the world is letting go in biological terms?

• 34:38Speaker 05

  Yeah, yeah. Well, I think we'll get there in terms of having the neural correlates of the mind revealing itself to itself, you know, the emergence of unconscious into consciousness or unconscious material into conscious awareness. It's a wonderful challenge. It's a huge challenge, but it's a challenge to embrace. And letting go very much is, again, a staple component of how the different teams do this work in terms of encouraging a willingness to let go. And when we started out doing our depression work

• 35:22Speaker 05

  and did that first trial, it was the first trial of a psychedelic in formerly diagnosed depression, you know, where that was the target population, a depressed population. It was the first modern study to do that. We visited Hopkins, our friends there, and were mentored on how to do the guiding. Bill Richards, Mary Cosimano, they were just so brilliant and, you know, wise in their guidance to us as to how to do the guiding in our trial.

• 36:06Speaker 05

  And so this phrase of trust, let go, be open, you'll hear a lot. I don't know who fairly it should be attributed to, but I would attribute it to Bill. Bill Richards, yeah, everything's borrowed. You probably got it from someone else, but it's such a key principle. It's almost like a mantra that you're trying to instill in people. Trust, let go, be open. And those different components where the trust is about therapeutic rapport. That again, you know, this goes beyond just intuition now. We formally measured therapeutic rapport.

• 36:47Speaker 05

  We do it even with just a single item, a visual analog scale item, the subjective rating scale item on the morning of dosing. And we find that it's a significant predictor of the quality of the experience that you have under the drug in the psychedelic therapy. And then the therapeutic outcomes X weeks or months later. So very powerful kind of chain of predictive components there. The trust, essentially important. And again, not just intuition, but the data pointing to that.

• 37:26Speaker 05

  Let go, there's a readiness, a readiness to surrender, to let go, to not resist. And we do measure that too, and see that it's predictive of response. And then the being open is about a willingness to go there, to confront, to be inquisitive. Something that's easier said than done can be terrifying, you know? When you're dealing with a very vulnerable population, it's probably more.

• 38:02Speaker 05

  The rule than the exception that they're carrying some significant adversity, life adversity or frank trauma that they've suffered. And so that message of be open, be willing to confront and to go there is really, you know, it's really powerful. Um, and that that's how it plays out and and often there is struggle. There's something going on that is, I don't want to be feeling this, make it stop. That can be nightmarish at times, but it's very, very strong. And with these big doses that we give, it's uh, it's very strong. And a- actually, a student um, that I've worked with, um,

• 38:48Speaker 05

  uh, I think now doing a PhD, Ari Brouwer is working on a fantastic project, characterizing the different phases of the psychedelic experience, where the early phase is dominated by um, negative emotions and and negative, uh, negative evalanced feelings of anxiety and struggle. And then it's a different story in the latter half.

• 39:12Andrew D. Huberman?

  Could I ask about that? Uh, first of all, I think that's fascinating and important to analyze the different phases. And again, I'm delighted here because people typically hear about a psychedelic journey, but we never really hear about the the kind of stereotypic components of the beginning, middle and end of that journey. We know that there's a peak and that there's a kind of a parachuting down and uh, et cetera. But um, when you say that typically there's an anxiety, maybe some negative valence in the early stage, do you mean about the sensations people are experiencing? Or about some prior event that's being called to mind that they're remembering? Um, likewise for the positive phase of the psychedelic uh, journey or trip. Are people, do they still call it a trip?

• 39:54Speaker 05

  Yeah.

• 39:54Andrew D. Huberman?

  All right, for the uh, I guess.

• 39:57Andrew D. Huberman?

  We'll use trip for the psychedelic trip. Are people feeling positive about the experience like ah, like there's been some sort of breakthrough or they're in a, in a calmer state? Or is it that they tend to be focusing on prior events that were positive? So in other words, is there a threading through of some concept that comes to mind for people? Maybe about an earlier trauma or maybe about a sense of self or a sense of other forgiveness? You know, it could be any of these things. But what do we know about the kind of finer details of all that?

• 40:30Speaker 05

  I would say the initial struggle is more against the general drug effects than pinning it on, on something specific. It's more that, you know, normal waking consciousness, we have a sense, generally speaking, if we're well or well enough, a sense of assuredness about what's what, you know, there's a table here and so on. And, and we have that assuredness to an extent about ourselves as well. It might be illusory, but we have it. And what the drug's doing is it's breaking down all of that and it's scary as hell, you know? And if it's a big dose, it's just like human nature to, to, you know, rage against that

• 41:14Speaker 05

  a bit and a bit like dying, you know? I don't want this. It feels like I could be dying.

• 41:21Andrew D. Huberman?

  I might lose my mind.

• 41:23Speaker 05

  Yeah, that too.

• 41:24Andrew D. Huberman?

  I never come back.

• 41:25Speaker 05

  Those two are the classics is, oh, but I might, you know, I might know that I've taken a psychedelic and I might even know a bit about psychedelics, but I still fear that I'm going to go mad. Or that I know that, you know, generally speaking, these drugs don't have a high, you know, fertility.

• 41:50Speaker 05

  Risk, I still think I'm gonna die, you know. And it's just, it's very palpable and that, and that comes up. So, yeah, that's, I mean, those are the core fears, that those two, and very reliably that comes up. And it's really like a basic drug action. It's dose dependent, but it's a basic drug action that is forcing something about the nature of the mind and the way it's made up that makes it feel that way. Oh, but it feels like I'm losing my mind. Or it feels like I could lose my mind, or that I could go insane, or that maybe I'm dying here and this is bad. Yeah.

• 42:32Andrew D. Huberman?

  You've talked many times before and have done really wonderful work looking at the changes in communication between different brain areas while under, while people are under the influence of psychedelics. And I think the gestalt of those, data, correct me if I'm wrong, is that compared to the non-psychedelic state that under psychedelic influence, there is far more, let's just call it interconnectivity or communication between a brain areas that typically aren't communicating, which probably is not surprising to people given the, the subjective effects of these, of these drugs. What is the evidence that after the psychedelic journey is over, that some, or perhaps all of that enhanced communication

• 43:15Andrew D. Huberman?

  across brain areas is maintained? And if so, what role do you feel that could play in these incredible positive therapeutic outcomes?

• 43:24Speaker 05

  Yeah. So we, we've had some recent findings in, in that direction where, yes, it's true. And, you know, the picture that says a thousand words that some people might be familiar with are these two circles. A project that we did in collaboration with some researchers, where ordinarily the communication is going on within systems. Like other regions of the visual system will be speaking mostly within the visual system. There'll be a kind of cliqueishness or a modularity to the quality of the communication in the brain.

• 44:07Speaker 05

  And then the cool finding with psilocybin was the first.

• 44:13Speaker 05

  Paper is that the communication, yes, it sort of transcends these modules and becomes much more inter modular crossing different modalities and that effect correlated with the magnitude of the subjective effects and then we replicated it with LSD using different methods and a new paper will come out soon with DMT showing a similar effect. It's a bit of a debate about what regions are most implicated, but the general effect of an increasing global functional connectivity is what we call it, or global communication in the brain.

• 44:48Andrew D. Huberman?

  And this is while under the influence of these drugs.

• 44:51Speaker 05

  This is under the influence.

• 44:52Andrew D. Huberman?

  So putting people into a brain scanner while they are under the influence of the drug, is that right?

• 44:57Speaker 05

  Yes.

• 44:58Andrew D. Huberman?

  That itself must be quite an experience, given that these scanners are small tubes. You're in a bite bar, you've got a bite bar in your mouth, that's a quite a, quite a study.

• 45:08Speaker 05

  You don't always have a bite bar, at least with the psychedelics, but yeah, you've got to keep your head still and, and you have the loud MR scanner noise going, but because it's regular, there aren't too many surprises, so it's actually surprisingly tolerable.

• 45:26Andrew D. Huberman?

  And you're in a hospital setting, so you're not worried about what would happen if you had a cardiac event or something?

• 45:31Speaker 05

  You've got professionals around and, you know, most people generally tolerate that setting quite well, surprisingly well, but yeah, we do all that and, and yes, we do see that opening up of the communication across systems in the brain and it does speak to kind of intuition about the subjective experience that, you know, different modalities might be blending with each other.

• 45:56Andrew D. Huberman?

  Is, sorry for interrupting, but I have to ask, is it thought that the activation of the serotonin 2A receptor is what's responsible for the increased communication between brain areas that under normal circumstances would not be communicating?

• 46:11Speaker 05

  Yes, so there's a few reasons why some modeling work, the computational modeling work that first identifies where the 2A receptor is and then looks at, models its basic effects on neural activity.

• 46:25Speaker 05

  Will recapitulate the, or recreate the effect that we see actually in the data with the scanning. So doing the computational modeling, you can see the same effect by knowing where the key receptors are and then making them do a certain thing that we know psychedelics do.

• 46:49Andrew D. Huberman?

  I can imagine two possibilities, and I think it's important to distinguish between these two. One possibility is that the activation of this serotonin 2A receptor leads to increased connectivity and thereby auditory and visual hallucinations emerge, changed patterns of thinking emerge, et cetera. That's sort of the obvious interpretation, but the scientist in me has to ask, is it possible that all of that increased connectivity is occurring and yet that is a distinct phenomenon layered on top of some other effect of the psychedelic drugs impacting access to the unconscious,

• 47:29Andrew D. Huberman?

  hallucinations. In other words, is it the increased connectivity that's leading to the subjective experience? Or are those two things happening in parallel?

• 47:37Speaker 05

  Well, they happen in parallel and they map to each other, but the question of causality, what causes what, is the tricky thing where I would suggest that the causality is circular, that they influence each other. And this gets a bit philosophical, but it kind of matters because otherwise, you know, there's a trap that it's easy to fall into where you're thinking that it's all about the brain action causing the subjective experience. And that's typically what we do in cognitive neuroscience. It's kind of like the sort of first port of call

• 48:19Speaker 05

  kind of materialist approach. But one can be a materialist essentially, but still appreciate that circular causality that mind also interacts with brain. And it's so hard to pick the two apart. And there is a kind of essential dualism where subjective experience is a thing in and of itself. But that's not to divorce it from what's going on on the biological level.

• 48:44Andrew D. Huberman?

  The reason I ask is because, as I understand it nowadays, there's a bit of a movement within the scientific community that studies psychedelics to develop drugs that can essentially cure or alleviate many of the symptoms of depression or trauma that are built off our understanding of how psychedelics like psilocybin. And here I'll throw MDMA in there, although classically not a psychedelic. It kind of gets lumped in. We can get back to that later. But that do not produce hallucinations or massive changes in subjective experience. Actually, I think this is what initially got us into conversation on Twitter. As I had learned about this paper published out of a group at UC Davis

• 49:29Andrew D. Huberman?

  that essentially modifying psychedelics so that they have potential therapeutic application for the treatment of depression, but zero hallucinogenic properties.

• 49:40Speaker 05

  Yeah.

• 49:41Andrew D. Huberman?

  And I thought, wow, this is going to be a very controversial thing in the world, right? Because the history of psychedelics, as you pointed out, has been one of people accessing different modes of thinking, feeling, seeing things, these letting go, trust, et cetera, therapeutic relationship. And here we have, I don't want to say pharma, because it's not really pharma, but we have laboratories who are trying to tease apart the activation of receptors independent of all that subjective experience in order to essentially treat the same conditions. I'd love for you to comment on this, where you think it might be going. And, you know, whether or not you think that's the right or the wrong approach, if it has any validity at all.

• 50:22Speaker 05

  It is pharma, it's just smaller pharma, sort of startup pharma.

• 50:26Andrew D. Huberman?

  Okay, so because pharma would like to have drugs that can cure depression, but don't make people hallucinate, is that correct?

• 50:31Speaker 05

  Oh, they would, and patients might, and the system would love it, because the system is used to it, it's medicine.

• 50:39Andrew D. Huberman?

  Right, and it doesn't give this, this, um, uh, mental imagery of, uh, you know, the summer of love in San Francisco, or of, of, you know, kaleidoscope eyes, right? It's, it's more, uh, you could imagine the, um, more, to be careful with my wording here, um, those who would not be inclined toward that would, might, might embrace a therapeutic that, that is strictly effective at treating depression with no hallucinations.

• 51:05Speaker 05

  Yeah, and it doesn't look like, uh, you know, an individual lying on a sofa, crying their eyes out, uh, um, about, you know, the life that they've lived, um, and that deep catharsis being life transforming. It's very different from that model. I'm skeptical of it, um, I, for a few reasons, um, and one is that I, I can't see the logic.

• 51:39Speaker 05

  I can't see the pieces fit in a way that's compelling. And I'm also skeptical because I think it could easily be wishful thinking because of that point that patients would like it, and the system would like it, and I just, you can't, you gotta bear that in mind as well. So wouldn't it be convenient, you know, if it were true, and you could get the therapeutic action without the psychedelic effects?

• 52:08Andrew D. Huberman?

  Well, in a way, that's a little bit of what microdosing seems to be designed to do. Like you said, take dosages that are below that, that perceptual, or, you know, awareness of some effect threshold over a longer period of time in an attempt to ping the circuits or twist, you know, uh, alter the circuits, but not hallucinate.

• 52:27Speaker 05

  Yeah.

• 52:27Andrew D. Huberman?

  Not have a catharsis.

• 52:28Speaker 05

  So if, if microdosing can do that, and it's sub perceptible, then microdosing isn't psychedelic action? Because where's the psychedelic action? When psychedelic, when defined, means psyche revealing.

• 52:43Speaker 05

  You're not getting that effect. You might be getting the pharmacology. You might be getting some direct serotonin 2A receptor agonism that could be driving a therapeutic response. But you can get that with SSRIs as well, you know. And so my point is, what's, what's new? Okay, maybe it's a bit new in people are now developing direct 2A agonists rather than indirect through a serotonin releaser like the selective serotonin reuptake inhibitors, the SSRIs like Lexapro, you know.

• 53:15Andrew D. Huberman?

  Are there any SSRIs that selectively agonize, which folks, by the way, means activate in a good way. Agony sounds terrible to those non-informed might think that mean that disrupt, but that can activate the serotonin 2A receptor? Are there any drugs that will do that that are not psychedelic? I'm not aware of any, but then again, I'm not a psychopharmacologist.

• 53:39Speaker 05

  There are. I mean, are there any that are licensed and used as medicines in psychiatry? I actually had this debate recently on social media and I couldn't see, I couldn't see a compelling example. I saw 2A agonists that were used for other things. You have a compound like liseride used in treating Parkinson's, but actually it's more of a dopamine agonist.

• 54:04Andrew D. Huberman?

  Right, so they're always hitting other things, right?

• 54:06Speaker 05

  Yeah.

• 54:07Andrew D. Huberman?

  They're always tapping other neurotransmitter systems.

• 54:09Speaker 05

  Or they've been used for other things. So is there, is there a selective serotonin 2A receptor stimulator, an agonist, that it isn't psychedelic, that is therapeutic in psychiatry? And the answer firmly is no. I haven't seen it yet. Will they develop one? Well, for patients' sake, I hope so, because it would be great. Let's wait and see. If they do, I doubt it will be psychedelic and I doubt it would have much to do with psychedelic therapy. And it would be much more like the system we're used to of chronic pharmacotherapy. Take your drug every day. Let's, let's hope they find it and it works for patients' sake.

• 54:52Speaker 05

  But as things stand right now, I'm a little skeptical. Now, some of the findings that are being seen that are really exciting, fantastic work being done, showing things like increases in the communication components of neurons, dendritic growth, spine growth, synaptic spine growth.

• 55:17Andrew D. Huberman?

  Yeah, by the way, folks, just I'll interrupt for the not necessarily spine, the bone, you know, the not the cerebral column, but spines are these little like little tiny twigs with bulbs on the end of of neurons that are allow for communication points between neurons. So neuroplasticity is often associated with growth of dendrites and spines and so forth, which is what Robin's referring to. That reminds me, and I just want to make sure that we close the hatch on the earlier answer because I interrupted you. Is the increased connectivity between or communication between brain areas that's observed while people are under the influence of the psychedelic also observed later after the effects of the drug wear off?

• 55:57Speaker 05

  Yeah.

• 55:57Andrew D. Huberman?

  And then I'll just throw in another question there because we're on to this topic now. To what extent do we think that neuroplasticity, structural changes in neurons, functional changes in neurons are responsible for that? And how long does that last? Let's say I take, let's say I come into your clinic. I'm a, I mean, subject in your experiment, I take do come in in the morning, I do my psychedelic journey, five or six hours later, I'm parachuting back to reality, as we call it, and then I go home. Increased connectivity lasts for how long? And how long are the structural brain changes occurring?

• 56:34Speaker 05

  Well, you're asking fantastic questions, and partly because we don't have the answer yet. But we do have some, we do have some data. And so we have looked at, first of all, the, in a sense, the functional plasticity or what we assume it to be, or at least the functional changes, the increase in communication across systems, that increase in global connectivity, functional connectivity. Do we see it after the trip? We know we see it during the trip, pretty well replicated, correlating with intense drug effects. Do we see it after the trip? Well, the answer is, we've seen it in two different depression cohorts, psilocybin therapy for depression.

• 57:15Speaker 05

  In one study where we looked the next day, we saw it, a kind of residual

• 57:23Speaker 05

  effect, similar to what you see acutely, being seen the next day. And then in a subsequent study, we saw it also three weeks later. So we've seen it in two independent data sets. This decrease in modularity is how we measure it. It's the same thing, essentially, broadly speaking, it's the same thing. An increase in global connectivity, functional connectivity. And actually, unpublished, we've seen it in healthy volunteers on a correlational level. Not on an absolute change level, but if you look at its relationship to a mental health outcome, and this is an important thing to stress with the depression work.

• 58:05Speaker 05

  We saw a relationship between the magnitude of that change, the decrease in modularity or increase in global connectivity, and the improvement in symptom severity.

• 58:16Andrew D. Huberman?

  So interesting.

• 58:17Speaker 05

  Yeah.

• 58:17Andrew D. Huberman?

  I mean, what I, and just to state it a different way. So what Robyn's referring to is when you say modularity, as neuroscientists, we think of the the different modular networks of the brain that, you know, the eye talks to a region of the thalamus involved in vision, which talks to the visual cortex, which, you know, eventually converges with auditory information, of course. But there's a separation or modularity of function. This increased connectivity is cross-modular in during the trip, but afterwards as well. And you're saying that that correlates very strongly with the strength of the therapeutic outcome for depression. I mean, the, the logical extension of that is that extreme modularity of brain function is depressive in some way.

• 59:01Andrew D. Huberman?

  Now, we don't want to go too far, but what does that mean? That increasing crosstalk between different modules of the brain?

• 59:10Andrew D. Huberman?

  Is so strongly correlated with a positive therapeutic outcome.

• 59:14Speaker 05

  We don't know, other than that as a relationship. I mean, this is, this is the thing, we need to be a little careful not to run with it too far. I mean, there's some things that it suggests. I think it suggests a more flexible uh, mode of brain functioning. If you're not getting stuck in modules or the modules aren't um, excessively cut off from each other. But you see different things with, with different presentations. If you were to look at cognition, sharper cognition is actually associated with more modularity. So it's a rule that's a little slippery and we need to be careful with it.

• 59:57Andrew D. Huberman?

  I, I, I just, again, I'll forgive me for intringing, but I think of, I have friends who are, um, I would say are on the spectrum, who are, um, very linear in their thinking and extremely intelligent in a, in the kind of classic sense of being able to ratchet through hard problems to arrive at a solution. And then I have friends who are, let's just call them what they are, from the creative communities outside of science that, um, are very expansive. Um, they see connections between many different things, but you, sometimes you have to, not all of them, but you have to catch their ideas with a butterfly net. And oftentimes what they're saying doesn't, sometimes just doesn't make any sense. Now, they also produce incredible creative works.

• 1:00:39Andrew D. Huberman?

  But to have a conversation with them is anything but a linear experience. They are not random thought generators. Um, but there's a non-linearity or randomness to their processing that's distinct from these other folks that I'm describing as on the spectrum. And of course, it's a spectrum, there's a whole range in between.

• 1:00:57Speaker 05

  Yeah.

• 1:00:57Andrew D. Huberman?

  Um, it sounds to me like there is some therapeutic value to being able to move along this continuum. From the more linear to the nonlinear, is that, is that correct?

• 1:01:08Speaker 05

  Well, I think so. Yeah, it's resonating what you're saying. It's speaking to my intuition that, you know, you could be very passy, you know, passing things up, chopping things up like an analytical scientist, like I'm doing.

• 1:01:22Andrew D. Huberman?

  A splitter, as we say in science. You're either a lumber or a splitter. Yep.

• 1:01:26Speaker 05

  Or, you know, the way I'm being very particular about what, when to call something psychedelic, you know, that, that kind of passy analytical way of thinking you would, you might associate with a more modular system, you know, whereas the system that's more globally interconnected and open, yeah, might be more flexible and creative and divergent in the associations and so on. So, yes, that's speaking to my intuition to how you're describing it. And I imagine if you take severe psychopathology, severe mental illness, like a depression, I've always thought that there's something intuitive about the term itself, like a depression in a landscape, you know, which is a whole.

• 1:02:09Andrew D. Huberman?

  Physical depression.

• 1:02:10Speaker 05

  A physical depression that it's easy to fall into, and if you do, it's hard to get out of.

• 1:02:16Andrew D. Huberman?

  So almost, if I understand what you're saying correctly, almost like getting stuck at one location on this continuum, because most people don't reside at one or extreme, one extreme or the other, full time, and kind of migrate back and forth between expansive states and more linear states.

• 1:02:33Speaker 05

  Like, like you do with low mood, you know? If you're healthy and inverted commas, you can feel your low mood, your disappointment, but you can spring back. But someone with...

• 1:02:42Andrew D. Huberman?

  And you know you can spring back.

• 1:02:43Speaker 05

  Yeah.

• 1:02:43Andrew D. Huberman?

  Right. Whereas the suicidal depressive person, or suicidally depressed person, somehow, at least in my understanding, there, there's something about the extreme depressive states and extreme anxiety states, something my laboratory is a bit more familiar with, anxiety, which alters the perception of time such that people feel like that negative...

• 1:03:09Andrew D. Huberman?

  State is going to go on forever? Or that if it goes away, that it's going to return at random?

• 1:03:17Speaker 05

  Yeah.

• 1:03:17Andrew D. Huberman?

  Kind of a vulnerability to the time domain.

• 1:03:20Speaker 05

  Yeah, yeah, that's it. And it's so tragic, but that cognitive bias in depression, that everything's hopeless and that there is no light at the end of the tunnel. Yeah, so, you know, if you were to get stuck in that rut and have that bias, then you're cut off from other things, other sensory modalities or modules, you know, cut off from the world, cut off from other people, stuck in your inner rut. And so, yes, I think we're sharing this intuition that a decrease in modularity or an opening up of the system, the brain, could relate to an opening up of the mind

• 1:04:02Speaker 05

  that is kind of enduring after the psychedelic dosing session. And, yeah, and the third replication was to see in healthies, an improvement in well-being, because they're healthy, we don't look at depression.

• 1:04:15Andrew D. Huberman?

  So these are people that are healthy, walking into the trial?

• 1:04:18Speaker 05

  Yeah.

• 1:04:18Andrew D. Huberman?

  Take psilocybin twice?

• 1:04:21Speaker 05

  Well, actually, they do, but the first dose is one milligram, which they don't feel. It's a placebo dose.

• 1:04:27Andrew D. Huberman?

  Quote, quote, micro.

• 1:04:28Speaker 05

  Yeah, we sticky G on their heads to measure their brainwaves during each dose. And one milligram, you see no change. So we, I think.

• 1:04:40Andrew D. Huberman?

  Take that, you microdoser. No, I'm just kidding. I mean, nothing against the microdoses. I've always just been a little bit skeptical, based on my conversations with the scientists actually doing the work with psychedelics. It seems like the answer keeps coming back. Do one or two, maybe three?

• 1:05:02Andrew D. Huberman?

  Macro doses in a controlled, safe setting.

• 1:05:05Speaker 05

  Well, that's compelling. The evidence for that is compelling and that's what's making all the difference right now. And microdosing is just appealing. But again, you know, science isn't about what we want to believe. It's about what's actually coming through and what seems to hold up, you know, to testing.

• 1:05:25Andrew D. Huberman?

  Would you say that's right, that one or two or three sessions? And how how far apart are those typically spaced in time?

• 1:05:32Speaker 05

  Yeah, typically one, two, three weeks across the sites is the way people are doing the psychedelic therapy dosing sessions. Two sessions, you know, Hopkins, Imperial, NYU. That's been a kind of default to we actually use three in a current anorexia trial, psilocybin therapy for anorexia. Two patients left to see after nineteen who've gone through the trial. Very exciting results there.

• 1:06:06Andrew D. Huberman?

  You're seeing alleviation of the the obsessive thought about food and a willingness to consume healthier amounts of food.

• 1:06:13Speaker 05

  Yeah, even improved weight at the long follow up. So.

• 1:06:17Andrew D. Huberman?

  So critical. I when we did an episode on eating disorders and I learned that anorexia nervosa, which by the way, folks, the rates of are not increasing. It's been pretty stable through time, despite what's said about social media and etc. But anorexia nervosa being the most deadly of all psychiatric illnesses, which is a big statement because, you know, manic depression, so called bipolar depression, has a 20 to 30 times the typical suicide rate. Basically, many anorexic, people with anorexia, I think is how it's now, is what one says, not anorexics, but people with anorexia often die.

• 1:07:00Andrew D. Huberman?

  Many of them die.

• 1:07:01Speaker 05

  Yeah, yeah. So tragic, so often young people as well. And similarly with suicide in terms of premature death. So the tragedy with psychiatry is so strong. And and so it's it's so rewarding to be doing that trial and to be seeing good results. I have to check myself a little bit that I'm I'm reporting on it in this really permissory way. And the trial isn't yet publicly released and and published. So it's still ongoing as well.

• 1:07:33Andrew D. Huberman?

  But that was three to three sessions.

• 1:07:35Speaker 05

  It is three sessions and I can't say what the dosage is because we still have. Um, there is a blinding component. Um, but there are three dosing sessions in there. Let's see now, I think they're two weeks apart.

• 1:07:50Speaker 05

  And we do the follow up. Yes.

• 1:07:55Andrew D. Huberman?

  I'd like to close out this description of the of the journey and the trip by extending past the day when people actually take the drug into this, what I've heard described as the integration phase. You know, you have to reintegrate, right? I mean, all this, all this increased connectivity during the session, hallucinations, insights, anxiety, letting go, maybe revelation, maybe epiphany. Okay, great. At what point is that consolidated? Meaning, are these patients or subjects in studies having daily conversation with their therapist? Are they journaling every day? And, you know, I want to keep in mind that most people are not going to be part of a clinical trial.

• 1:08:39Andrew D. Huberman?

  And of course, here, we're not suggesting what people do or not do. But let's just put it this way. Were people to use psychedelics? What is the way that people can maximize on the neuroplasticity and the brain changes in a positive way in the days and weeks afterwards? In other words, how long does this so-called integration last? And, you know, what, how far can we take this? I mean, I could imagine that. How often one chooses to think about the insights could also have an impact.

• 1:09:14Speaker 05

  Yeah.

• 1:09:14Andrew D. Huberman?

  Right? Because clearly, people went to raves. Clearly, people did psychedelics in the 60s. We don't know if, clearly, people do psychedelics now, but we don't have data on those people. You have access to the understanding of how they're spending their time and the therapeutic outcomes, which we haven't gotten to the numbers yet, but again, are incredibly impressive. You know, in upwards of, as I understand it, 60% or more, people getting relief from depression.

• 1:09:40Speaker 05

  Yeah, 70, yeah.

• 1:09:41Andrew D. Huberman?

  70%, incredible, especially when compared to the typical antidepressant treatments and so on. So what is this business of integration? How is it done properly?

• 1:09:54Speaker 05

  Yeah, yeah. Gosh, well, how long does it last as well? A lifetime, you know, life is a journey, like a trip is a journey. And there's always work to do, you know, as Jack Comfield says, after the ecstasy, the laundry.

• 1:10:13Andrew D. Huberman?

  I love that.

• 1:10:13Speaker 05

  Yeah, there'll be other good ones as well, I forget them. But yeah, so the work's ongoing and, and, and, yeah.

• 1:10:26Speaker 05

  But this gives you a foot up. It enables people to do the work more easily. And that's true of the classic psychedelics. It's also true, very true of MDMA therapy

• 1:10:39Speaker 05

  for post-traumatic stress disorder. It's really giving you a leg up, making it easier to do very, very difficult work, going back to a trauma, trying to digest it, process it, integrate it.

• 1:10:52Speaker 05

  So it's such an essential component of the treatment model.

• 1:10:58Speaker 05

  But one has to be realistic as well, you know, by saying, oh, integration lasts a lifetime. Well, people delivering a service can't be there for a lifetime. So what's the answer there?

• 1:11:13Speaker 05

  And people are wrestling with that issue right now. And I, I think one of the solutions might be that it's in a sense on you to a point, you know. The therapeutic team can treat you to a point. And then it becomes what you might call practice. In a similar way, that meditation is a practice. It's something that you have to keep up. And if it slips, then things could slip. And, and that's the way it is. Or you have a, another psychedelic treatment, you know. So people have even used this term of practice in relation to psychedelics, where there's a psychedelic

• 1:11:56Speaker 05

  practice, like there's, you know, a meditation practice. But I'm using meditation intentionally here because I actually think that meditative practice, spiritual practice, elements of spiritual practice could be a very important complement to psychedelic therapy.

• 1:12:22Speaker 05

  And I think it's probably doing something similar in terms of promoting an ability to sit with.

• 1:12:31Speaker 05

  A former colleague of mine said it quite well in relation to psychedelic therapy versus chronic pharmacotherapy or like SSRIs being on them all the time. So psychedelic therapy allows you to sit with rather than sit on. I thought that's quite good. Yeah, so, you know, the meditation, the mindfulness, the ability to, yes, be present-centered, but also present-centered and accepting. So if things come up, you can watch and process and then let go.

• 1:13:05Andrew D. Huberman?

  That holy grail of mindfulness.

• 1:13:08Speaker 05

  Yeah.

• 1:13:09Andrew D. Huberman?

  You know, uh, you know, awareness without reactivity, response. You know, I, I grew up in the Bay Area and you'd hear this language, right? And I'm not being disparaging in this. I have friends that are on the board of Esselin and work down there, you know, and I've gone there and it's, you know, and yet you hear these terms, right? Be responsive, not reactive, which to a neuroscientist is like.

• 1:13:32Andrew D. Huberman?

  Greats on me, which probably just means I have issues, but and surely I do. But you know, it was like, what does that mean? Right. It's sort of saying like, oh, to be the observer, but not be drawn into the experience. You know, and, and again, I don't want to be overly reductionist, but what I find so compelling about the emerging data, because it really is data on psychedelics as treatments for depression and trauma, namely psilocybin and MDMA, is that it really seems to allow people this space that, that is so commonly thrown around, you know, giving space between stimulus and reaction. I mean, Viktor Frankl talked about this, but you know, I've been reading a wonderful book called The Prince of Medicine, good dates back to the origins of medicine, very dense book.

• 1:14:15Andrew D. Huberman?

  People have been talking about this stuff and thinking about this stuff for thousands of years. Psychedelics seem to give people access to that better version of self, which is remarkable. What's also remarkable, it's perhaps worth pointing out, is that five years ago, I never would have been comfortable having this conversation. I would have been afraid to lose my job. Stanford Magazine this week just published an entire issue about psychedelics with how ketamine works, MDMA, psilocybin, with the appropriate cautionary notes in there, but clearly times are changing. Speaking of which, I know you're doing a trial on first time use of psychedelics. What inspired that and what are you observing?

• 1:15:00Andrew D. Huberman?

  And as you tell us that, please give us a few of the, the key contours. What's the dose? How old are these subjects? I'm assuming it's men, women, are they suffering from depression or not? Well, kind of what, what's the landscape of that study? And I, I, I realize this is still early days of the study, or maybe it's close to completion. It's not yet published, however, correct?

• 1:15:21Speaker 05

  It's not, it's not published, it's not submitted, it is completed. So this was one, another one of our COVID studies in a sense, meaning COVID hit and we had to finish the study and it was hard to finish the study because of COVID. That was true about psilocybin therapy versus escitalopram, Lexapro trial.

• 1:15:39Speaker 05

  Which is published, New England Journal of Medicine, but the

• 1:15:44Andrew D. Huberman?

  This was 20, that paper, by the way, folks, we'll provide a link to in the show note captions, as well as some of Robyn's other papers. I think that 2022 New England Journal paper is really fabulous, given it's the different dosages and the comparison to essentially what is microdosing and the comparison to cetalopram.

• 1:16:02Speaker 05

  Yeah, that's interesting that you you link the way we gave small doses of psilocybin to microdosing. We didn't think of it that way. We thought it was just a necessary placebo for the big, big dose, the 25 milligrams. But yeah, and so that we could say to everyone, we're giving you psilocybin and not be lying. Yeah, for those who got cetalopram, Lexapro for six weeks, they they got a very, very low dose of psilocybin. But it allowed us to standardize all the psychotherapy and so on. But the the other study that you're referring to was in healthies, healthy volunteers, middle aged, average age, I think was 40, so not your typical student study,

• 1:16:45Speaker 05

  that is so often the case in psychology research, you know, all the undergrads end up volunteering for your study. So this is more more of an age range and also I think it was an equal proportion of male and female. All the staff actually were female, which the staff were very proud of.

• 1:17:05Andrew D. Huberman?

  Although it produces its own potential confound, right? To have all one, one sex of of of staff.

• 1:17:13Speaker 05

  Possibly.

• 1:17:13Andrew D. Huberman?

  Yeah.

• 1:17:14Speaker 05

  They did a good job in the sense that we saw significant improvements in well being at the end of the trial. So let me describe the design. It was a repeated measures design, meaning people come in, you collect your baseline data and do a brain scan, and you give people a placebo. We gave people a placebo. And actually, let me rewind a little bit. Everyone's healthy volunteers, middle aged, never taken a psychedelic in their life, none of them. Entirely, you know, fresh, virgin people coming in. And and the plan is to give them their first ever psychedelic experience. So that's what we did in the study. But to do it, we have this repeated measures design where they'll first get a placebo.

• 1:18:00Speaker 05

  And we have the placebo so that we can do all the procedures, all the therapy, all the music listening, but not give a whopping dose of psilocybin. Again, we gave them a placebo dose of psilocybin, one milligram. We stick EEG headsets on during the experience to record the brain activity from the scalp, the oscillating electrical activity. And we do the MRI scanning before and after to see deeper into the brain. And we can look at the functional connectivity that we were referring to earlier and also properties of brain anatomy, which we did in this study.

• 1:18:39Speaker 05

  So the short story is that all of the changes that we saw, both psychologically and neurobiologically, were seen with the 25 milligrams. It all happened with that big whopping dose. And what did we see? Well, we did see significant improvements in psychological well-being. We saw what I call the entropic brain effect, which is actually formally quite accurate. We see an increase in the informational complexity of ongoing brain activity recorded with the EEG on the dose of psilocybin. The activity becomes more complex. It's harder to predict across time.

• 1:19:22Speaker 05

  It's more informationally rich. And that effect correlates, as it does very reliably, with the magnitude of the subjective effect. So the bigger the trip, the bigger the centropic brain effect. Now, pretty well replicated finding. But then the MRI seeing deep into the brain was probably our most exciting result, where we didn't just see some functional brain changes, but we've seen some anatomical brain changes as well. And we used a technique called diffusion tensor imaging that looks at the cabling of the brain, the white matter tracts.

• 1:20:03Speaker 05

  And we saw a change in major tracts, so we we sort of limited our search space to really thick tracts, really thick fibers. And the fibers that came through as changing were ones that traveled between the prefrontal cortex and the thalamus and the striatum. There were two tracts, two prefrontal tracts that changed, and they changed in the direction of a decrease in axial diffusivity, which could be interpreted as tract integrity, where a decrease would be an increase in tract integrity. It is something that you see in the developing brain, that axial diffusivity decreases.

• 1:20:48Speaker 05

  As a brain goes from being a baby to being an adult, axial diffusivity goes down. And then in aging and pathologies of aging, axial diffusivity goes up.

• 1:21:01Andrew D. Huberman?

  So this is in the opposite direction of of the results you talked about earlier in terms of brain connectivity of a sort of increased communication across areas, if I understand correctly, and I'm perfectly happy to be wrong, by the way, that this decrease in axial diffusivity is translates to a higher fidelity of communication between the prefrontal cortex and the thalamus and striatum as opposed to less. And your description of this as somewhat like the the transition from babyhood and childhood to adulthood speaks to the same, where we know that there's a massive culling of connections as opposed to growth of connections. So in other words, as we get older, we get better at doing certain things and less good

• 1:21:45Andrew D. Huberman?

  at doing potentially most everything else. Is that right?

• 1:21:50Speaker 05

  Ish, because the the change was anatomical and not functional. So the other stuff was is really measuring communication in in the brain by looking at how the activity fluctuates across time and whether those fluctuations in activity are synchronous between regions. And if they are, we say they're functionally connected, and we infer that they're talking to each other because they go up and down in synchrony. But when it comes to the anatomy, we're talking about the just static, you know, material stuff.

• 1:22:27Speaker 05

  And so we're seeing the fibers and a property of the fibers change. At least that's what we think. And recently, we had an independent person come in and reanalyze the data because, you know, one of those things, incredible finding requires, you know, credible evidence, really strong evidence. And I would say the evidence at the moment is one study, so we need to be cautious on that. But we did reanalyze it and use this correction procedure, free water correction, to be more

• 1:23:05Speaker 05

  sure that it was a change in the actual microstructure, rather than something to do with the extracellular space, the water surrounding the fibers. And it came through. In fact, the change was strengthened by doing this correction step.

• 1:23:22Andrew D. Huberman?

  So these are, this is neuroplasticity as the consequence of one first time session with 25 milligrams of psilocybin?

• 1:23:30Speaker 05

  Yeah, yeah. So we're excited. And the two different, you know, the second analyst coming in wasn't sure she believed it. And then she, you know, thought this correction technique might kind of kill the result. And then it came through and she's like, okay, now I'm excited too. So we'll see. We don't know what it means. What does it mean functionally? We don't know. How did the people change? Well, psychologically, as I said, their well-being improved. We did look at their cognition and we used a cognitive flexibility paradigm that looks at people's ability to notice a rule change and then flexibly adapt their behavior based on noticing this rule change.

• 1:24:15Speaker 05

  And people improved after the 25 milligrams and didn't significantly improve after the placebo dose. There weren't correlations with the DTI change, the cabling change and the psychological outcomes. But, you know, with these studies in smaller sample sizes, you don't always see those correlations come through. So it's something, we don't know what it means, but. It's a change in brain anatomy that's in the opposite direction to what you see in an aging brain or with pathology of aging. And it's what you see in a healthy brain as it goes from, you know, normal neurodevelopment into adulthood.

• 1:24:58Andrew D. Huberman?

  Very, very exciting and intriguing, and I appreciate that you highlighted that it's just one study, although from everything you've said, it sounds like it's been done with immense rigor. So we will eagerly await the publication of that study and so we can peruse all the data and the subsequent studies. I want to hear a bit about the study that you have been carrying out on the use of psilocybin for the treatment of fibromyalgia. I'm intrigued by fibromyalgia because I have a good friend who also, I won't reveal who it is, and no, it's not me. This isn't the I have a friend thing, who also is a scientist, who sits at a fairly high position in the National Institutes of Health,

• 1:25:38Andrew D. Huberman?

  who quietly has expressed to me that they are incredibly frustrated with the fact that the standard medical community has largely ignored fibromyalgia. And that for many years, it was kind of lumped with things like chronic fatigue syndrome and other so-called, again, so-called, I'm not saying this, but people often refer to these as, oh, it's psychosomatic, that's all in your head. Which as a neuroscientist is a ridiculous statement to hear because it's all in your head, your brain is in your head. After all, your physiology and your psychology are influencing each other. Of course, and the world is starting to appreciate that more. But first of all, maybe you could tell people what fibromyalgia is?

• 1:26:21Andrew D. Huberman?

  What inspired you to do a study on fibromyalgia? Using psilocybin of all things, because that's surprising to me. And if you Are allowed to, or if you have access to the data in mind, share with us a little bit about what you're discovering in that in that study.

• 1:26:39Speaker 05

  Sure, yeah, happy to. So again, it's salicylbin therapy and the population is fibromyalgia syndrome. So this is people presenting with a generalized chronic pain. So unlike some other pain disorders where the pain is focused, you can say it's my lower back, which is very common, chronic lower back pain. This is more generalized. And for that reason, it's hard to sort of know what it is. And that's why it's been a controversial space in medicine. And it's been, yeah, it's had that charge thrown at it that maybe it's psychosomatic and just to your point, is anything ever, you know, independent of the

• 1:27:23Speaker 05

  mind anyway. But this is actually a fascinating space for how, you know, subjective experience, lived experience and the mind can influence the body. Because there's some really interesting literature around the etiology, like the how the pain has come about, in a sense like what caused the pain, what's the story there. And ahead of the trial, I would say to my colleagues, let's just be careful because there is some fascinating literature around things like a background of trauma and how that can relate to issues related

• 1:28:08Speaker 05

  to inflammation and how that can express into things like fibromyalgia syndrome. I just said, be very careful there because if you go in with an assumption that there's some buried trauma, for example, then there's that whole other side of psychoanalysis that massively tripped it up around false memory and so on. And so please don't hold prior assumptions that you're going to uncover buried trauma in every case. Now, the team have treated, I think, eight people.

• 1:28:40Speaker 05

  And it's going, it is going very well. Again, I just wanna be careful with how I describe it to ma, you know, to manage expectations and not get too carried away. But I check in with the team every week and they're still based in London doing the work. And it's remarkable what I hear about the profound experiences that people have under the drug. In this study, we only give one dose. It's a very mechanistic study. We actually have the EG cap on in the sessions, like in the healthy volunteer study, but this time now taking it into a clinical population.

• 1:29:24Speaker 05

  And.

• 1:29:26Andrew D. Huberman?

  So they're in the, they're, they are wearing an eye mask under the influence of 25 milligrams of psilocybin. Most of them probably have not done psilocybin before. So it's a little bit like the first time study in some sense. They have fibromyalgia that's debilitating in some way. They, they don't, they want, they don't want it, obviously. And during the session, are they thinking about their pain? Are they being told to think about their pain?

• 1:29:56Speaker 05

  They're not being told to think about the pain. In, in fact, as I understand it, while there is a therapeutic model around acceptance of the pain, it isn't, unlike some of the PTSD work, you aren't encouraging them to focus on, you know, the index trauma and then, you know, work through it and try and digest it. We don't, we don't do that with the pain. So the pain's there, but there isn't an invitation to focus on it. And that's probably one of the differences with classic psychedelic therapy versus MDMA therapy. Arguably MDMA therapy is more like, a bit closer to traditional talk therapy, where there is more dialogue.

• 1:30:41Speaker 05

  People are able to talk on MDMA.

• 1:30:43Andrew D. Huberman?

  In the MDMA trials, do you know whether or not they used eye masks? Or, because this seems to be an important distinction between, as you described, the therapeutic trip versus the trip that one does, you know, going into the woods and taking, you know, taking psilocybin in the woods or at a party or.

• 1:31:06Andrew D. Huberman?

  While staring at a poster or a leaf. Again, I'm not trying to trivialize those experiences. I mean, obviously, they can be profound, but so I'm told. But the MDMA trials seem to involve, as you said, more directed dialogue.

• 1:31:27Andrew D. Huberman?

  And sometimes even kind of empathic connection between people by their actually looking at one another. You know, the eyes and eye contact being such a key part of the human social cognitive connective networks. So do you know if they put eye masks on people during the therapeutic session?

• 1:31:46Speaker 05

  I'm pretty sure that they have the eye masks there.

• 1:31:49Andrew D. Huberman?

  Right, because a lot of the MDMA work, and I was part of an MDMA trial. Was, as I understand, geared toward developing, because it's an empathogen, empathy toward the self.

• 1:32:02Speaker 05

  Yeah, I'm pretty sure they have the eye masks there. But they probably, and it's a great question, because you could formally test this, they probably don't use them as much. The thing is with the classic psychedelics, if you're looking at your guides, your facilitators, and their faces are melting or whatever.

• 1:32:20Andrew D. Huberman?

  On MDMA, you just might really start to feel more connected to your therapist.

• 1:32:24Speaker 05

  Yeah, they might look especially beautiful and, you know.

• 1:32:26Andrew D. Huberman?

  Sure, yeah.

• 1:32:28Speaker 05

  And, and yeah, there's that fascinating effect of loving, you know, the people that you're with. And so, yeah, I imagine they talk more and use the eye shades less. And it is more interpersonal rather than like intrapersonal or going inside. They do use a fascinating terminology that some people have critiqued, but it is a very interesting phenomenon. And it's this notion of the inner healer. They use that that language a lot. It's been critiqued because it sounds very suggestive, you know? And that's probably one of the vehicles here, driving the therapeutic process is suggestion. I think we have to be honest about that.

• 1:33:11Speaker 05

  But so when they go inside, that's another term that we use very much in the classic psychedelic therapy work, you go inside, you know, you put the eye shades on and people are encouraged to go inside, you know. But when they do that, in the MDMA work especially, they might be told explicitly and listen to the inner healer, you know, and that kind of language. So you could see how a cynic or a skeptic could come in and see that as some kind of like suggestive priming or biasing. I think they have a point. Skeptics often do, but I don't think it's all of the story.

• 1:33:53Speaker 05

  And just briefly, because it's an interesting point, speaking to that point a bit, in our psilocybin therapy versus acetalopram trial, we measured pre-trial expectancy and we did it for both conditions. So, you know, what kind of improvement do you expect with the Lexapro, the acetalopram at the end of the trial? And what kind of improvement if you go into the psilocybin arm and get a big, two big doses of psilocybin? What kind of improvement do you think you'll see in that, in that arm? And of course, it was a coin flip as to what arm people went into and there was no crossover.

• 1:34:33Speaker 05

  And what we found was that it was true that we had a sample bias. So most people had higher expectations, on average, there were higher expectations for psilocybin and its efficacy or effectiveness versus the SSRI, the Lexapro. However, when we looked at the correlation or the predictive relationship between pre-trial expectancy and response, we saw that pre-trial expectancy for the acetalopram predicted response to acetalopram across virtually every single measure, all these different measures of depression and anxiety and wellbeing.

• 1:35:16Speaker 05

  And and I think none of the scales, I'm pretty sure it was none of about twelve or so mental health rating scales. Was there a relationship between pre-trial expectancy? Even though it was high, it didn't predict, pre-trial expectancy didn't predict response to the psilocybin therapy. So that was a bit of a, you know, smash on the head for the idea that that classic psychedelic therapy is some kind of placebo response. And I think it's so important to address that question. Um, because um. If it doesn't come through, as it didn't, as it didn't come through, then it

• 1:35:59Speaker 05

  it opens up even more intrigue about, well, what is it then? If it's not just a placebo response or a super placebo response, like an amplification of the placebo response, then it must be something else. And how intriguing it has a direct therapeutic action. It must be something. And we don't yet know what it is. I talked about the the residual, you know, increase in global connectivity. That's one possibility. But the truth is, we're we're just scratching the surface.

• 1:36:32Andrew D. Huberman?

  And yet the therapeutic outcomes are, again, just so marvelous, marvelously impressive. Um, I'm curious as to why, as, well, there are that many labs, but the the laboratories that are focused on classic psychedelics for the treatment of depression and and now, as you mentioned, promising results for anorexia and fibromyalgia as well, although preliminary prom, very promising. Uh, why the lack of attention toward LSD? Um, is it that the LSD trips are just too long? Is it that they are qualitatively different? Um, are there any data on um, non-microdoses of LSD? And here I want to be very careful because I I learned through by interactions on social media

• 1:37:17Andrew D. Huberman?

  that this term microdose is very misleading. And in some cases can be dangerously misleading because, as you mentioned earlier, the effective. Psychedelic dose, or, you know, the effect, meaning that can induce a real trip with hallucinations, et cetera, of LSD is actually in the microgram range. So some people hear microdose and they think microgram of LSD is a, micrograms is a microdose, when in fact, a macrodose of LSD can be measured in micrograms.

• 1:37:51Speaker 05

  Yeah.

• 1:37:51Andrew D. Huberman?

  Right? So this is where, you know, in the absence of scientific training, people can really go astray, or even in just in that lack of understanding of the metric system. And since now you're a

• 1:38:02Speaker 05

  Yeah.

• 1:38:03Andrew D. Huberman?

  You're a recent rival to the US. Fortunate for us. Sorry. England's losses is the US's gain by Robyn's lab moved from England to the United States recently. So score one for us. But why isn't there more use of LSD in these trials?

• 1:38:23Speaker 05

  I think it probably is the duration of the trip. It used to be stigma. And it was easier to get your psilocybin study through because others were, they were getting that through. So there was the likes of Franz Wohlenvider in Zurich and Switzerland, and then Roland Griffiths coming along and doing the psilocybin work at Hopkins. So you could appeal to that precedence and say, well, they're doing it over there, you know, can we not do it in little England? So that's how it works for us. We did actually go on and do an LSD study once we'd kind of laid the foundations for doing this kind of work. And it was a brain imaging study.

• 1:39:07Speaker 05

  It was a really extensive one, actually, where we used both MRI and another modality called MEG, sort of super EG in a sense. But, you know, why didn't we, why didn't that turn our heads to think, oh, should we not be doing our trials with LSD? It's, it does have something to do with the pragmatics, like a study day with psilocybin is long enough.

• 1:39:34Andrew D. Huberman?

  It's a four to six hour trip.

• 1:39:36Speaker 05

  Yeah, and the FDA ask us to have the people in the lab until eight hours post-dose, which personally I think could be quite excessive, especially if it's a low dose. You know, if you have that in the placebo condition as well, it becomes impractical.

• 1:39:56Andrew D. Huberman?

  Yeah, scientists are not paid nearly enough to warrant the, there's no such thing as overtime in, for the graduate students in post-docs.

• 1:40:03Speaker 05

  Yeah, it's often those, you know, more junior members that are doing that really hard work.

• 1:40:08Andrew D. Huberman?

  Uh, it was described very well to me by a student when I was a graduate student, said to me, they really can't afford to pay us by the hour. Cause we used to work, he was an electrophysiologist, so he would run experiments, no joke, folks, three to five day experiments, sleeping in bouts of two hours here or there, in a dark room with a bunch of equipment and recordings. So these are long, long acute physiological, electrophysiological recordings. So, um, yeah, no, no scientist does it for the money, I promise you.

• 1:40:42Andrew D. Huberman?

  That there is money in pharma, there is not money in, uh, personal income, uh, it's not lucrative for the basic scientist. So, yes, LSD is what, uh, anywhere from eight to 15 hours, something like that.

• 1:40:57Speaker 05

  Yeah, 15 would be a little long, you'd be a bit worried if you were still tripping at that time, maybe with a really big dose.

• 1:41:02Andrew D. Huberman?

  Oops, no, just kidding.

• 1:41:04Speaker 05

  But yeah, eight hours plus and dose dependent, yeah, if it's a bigger dose, it's a longer experience. But, you know, if you're gonna dose at say, you know, 10 a.m. in the morning, which is more or less how it often goes, then at 6 p.m. still feeling the effects. And then how long do you wait now to kind of close things out before they can go home? Even with psilocybin, you have people still at work into the evening and the staff are always there later, of course, because they gotta pack up and. Yeah, so these are long days and it's just, it's too much, you know?

• 1:41:44Andrew D. Huberman?

  That makes sense, you know, practical constraints. I learned from a recent guest on this podcast that we recorded with Dr. Satchin Panda, who was a colleague of mine when I was down at the Salk Institute, pioneered a lot of the studies on so-called intermittent fasting, that the reason the intermittent, that the eating period in these studies in animals and now on humans is eight hours, the sort of feeding window in these studies, is because the graduate student was going to otherwise lose their relationship because their significant other says, listen, you can be in the lab for 12 hours. That meant some hours before the experiment, then eight hours, and then some hours afterwards, but you can't stay in there longer. And many people use the eight-hour feeding window as a consequence. So the science has to exist and be carried out in real-world frame.

• 1:42:29Speaker 05

  It does.

• 1:42:32Andrew D. Huberman?

  MDMA is a little bit, a little bit shorter, right? It's about a four to, it's also about four to six hours, correct?

• 1:42:38Speaker 05

  Yeah, it's kind of similar to psilocybin. Yeah, it is, and actually in the MAPS work, they re-dose after a certain point.

• 1:42:44Andrew D. Huberman?

  The booster.

• 1:42:45Speaker 05

  They have a booster, optional booster, yeah. So, so there is that. And now people are thinking, well, even these psilocybin sessions are long and expensive. And if you have to have two staff members there all the time, that's expensive. That's where most of the expense is, is in the staffing. So can we abridge the experience, make it shorter, and get away with it and get similar kind of therapies outcomes? So there's a lot of interest in that direction.

• 1:43:17Andrew D. Huberman?

  May I ask about, sorry to interrupt, but I want to make sure I don't forget to ask about combination psilocybin MDMA therapies. The reason I ask about this is, and here truly not me, but I know people who do self-administered combination psilocybin and MDMA. I think I have this right, I think it's called a hippie flip. There's another one that involves LSD too. Again, I'm not suggesting people do these kind of drug combinations, but the way it was described to me was that the psilocybin, because it's so serotonergic... Sometimes can be not a downer, but can have a bit of a kind of a murky feel to it.

• 1:43:58Andrew D. Huberman?

  Some real deep introspection, sometimes in the darker realms of one's psyche, depressive thoughts, et cetera. Not that it necessarily stays that way throughout the trip, but that the MDMA, because it has a very strongly serotonergic, but also dopaminergic. I mean, it has an amphetamine component, cocaine-like, in fact. If you've ever seen someone on MDMA, their pupils are about the size of quarters. For a reason, they're in extremely, extreme autonomic arousal compared to a sedative, which, by the way, would constrict the pupils. So they described the use of MDMA to kind of balance out the affect component of it.

• 1:44:42Andrew D. Huberman?

  What are your thoughts on combination psilocybin MDMA? Does this hold any therapeutic potential? This is obviously backyard chemistry in the sense that people are cowboying this stuff on their own, which, again, I don't really recommend. I like to see the science go first, but I understand this is how it works in the real world. Yeah, what are your thoughts on combining compounds?

• 1:45:05Speaker 05

  Yeah, well, I guess they're cowboying it in recreational contexts, but also underground therapists do work with this combo.

• 1:45:13Andrew D. Huberman?

  That's what I'm referring to. So I'm not talking about people partying with this stuff. I'm talking about, there are thousands now of therapists that offer psychedelic therapies, illegally, really, because it's not legal, at least not in the US, to possess or sell, but that are doing this.

• 1:45:29Speaker 05

  Yeah.

• 1:45:29Andrew D. Huberman?

  So that's really why I'm asking.

• 1:45:30Speaker 05

  Yeah, and I think there's something to be said for, one has to be careful with this as a scientist, but if they're doing it, are they using some kind of trial and error? The same is true, of course, with the longer history of psychedelic plant medicine use. If by plants, we include the fungi as well, so in the extended sense, plants. You know, there will have been trial and error there. It might not be as systematic as the science we do today, but maybe there's been a learning process and maybe what they do, they've come to because they found it works. So by that principle, I'm interested in that combination and whether it does offer some advantages, maybe in certain patients.

• 1:46:15Speaker 05

  You know, if we, one of the buzz terms in medicine these days is precision medicine. Precision medicine and personalized medicine. So maybe there are certain cases where, you know, introducing, um, say psilocybin after the MDMA or the other way around could offer some advantages. And the differences are interesting, you know. Psilocybin can get you to deep places, maybe, you know, the kernel of your suffering and, and uh, major life experiences and complexes that are causally linked to whatever the pathology that you're presenting with.

• 1:47:01Speaker 05

  Um, but it can do it sometimes quite aggressively, you know? And if it's, say, post-traumatic stress disorder, it can be overwhelming and you can fight it. And really it's that, it's that, you know, the resistance is really challenged and they fight back. And the therapeutic breakthrough and the progress isn't happening because you've agitated the defense mechanisms. Whereas what MDMA offers is something arguably more directionally reliable in terms of, in terms of the valence, like it's more directionally positive generally in MDMA experience.

• 1:47:42Andrew D. Huberman?

  Hard to have a bad time on MDMA.

• 1:47:43Speaker 05

  Yeah, yeah.

• 1:47:44Andrew D. Huberman?

  To be quite blunt, I mean, but one of the concerns I I had with MDMA, I've never done it recrea-, I have had not and have not ever done it recreationally. But when it was done in this therapeutic setting, I realized because there was music on at the beginning, I asked, I actually asked them to turn it off because I realized that the, um, the music was becoming such an attractor to my attention that I suddenly was starting to think about music and my love of music, which was not the focus of the session that I saw, was there, you know, for. Um, and I'm glad that they did turn the music off because the moment they did, I was able to drop in within the I'm asked to this, to the sort of go inward and address some certain issues that at least to me felt key and productive.

• 1:48:25Andrew D. Huberman?

  Um, so that seems to be the kind of hazard with MDMA is that, uh, it's such an empathogen that, uh, one could, uh, start to, you could go down any number of different, um, rabbit holes.

• 1:48:38Speaker 05

  Yeah, yeah, but but it's also, it's a strength because you, well, you know, the classics like psilocybin can take you there very reliably, but maybe a bit aggressively. MDMA makes it easier to go there. And that's its strength. And that's why that marriage of MDMA therapy for PTSD in particular is a good combo. It works because you are gonna go there. In a sense, you have to to really make the therapeutic progress. You're gonna have to go back there. But we're gonna set it up so that you can go back there and feel safer and more trusting and be able to go back there.

• 1:49:20Speaker 05

  Whereas you've never otherwise been able to go back there without, you know, dissociating or having, you know, horrible flashbacks and so on. So that's the strength that it offers. I guess the limitation would be that maybe it doesn't take you as deep as the classic psychedelics. And I tend to think, I'm biased on this one, that there's a kind of honesty to the classics in that it is it is hell as well as heaven, you know? And that's the psyche. It isn't all roses.

• 1:49:54Andrew D. Huberman?

  I really appreciate that you bring that up because I think that there's such a fear of so-called bad trips. There's such a fear in non-psychedelic states to to avoid the painful. And everything, everything we know from trauma and the treatment of trauma. And we've had several guests on here. My close colleague, close, close colleague at Stanford, Dr. David Spiegel, our associate chair of psychiatry, is clinical hypnotist, amazing, amazing human being and scientist and clinician. Has really just, you know, like embedded this in my mind that the only way to deal with trauma is to get right up next to that trauma, to the point where some relief is experienced.

• 1:50:37Andrew D. Huberman?

  There is no other real way. And so I really appreciate that you're saying that the classic psychedelics may offer the, with a very strong nudge, perhaps, the opportunity to get into the uncomfortable in a way that MDMA or some non-classical psychedelics perhaps do not.

• 1:50:57Andrew D. Huberman?

  We were talking about timeframes or duration of trips and these different compounds and how they differ and how they're similar. I'd love for you to educate me on DMT and some of the work that you're doing with DMT. My understanding is that it's a very brief trip, minutes. People I know who have done this, again therapeutically, actually, I'll just point to one very exciting, I think, group and initiative, which is the Veteran's Solutions Initiative, which is a group, this is carried out in Mexico, but in conjunction with laboratories at Stanford and elsewhere, who are evaluating the neural changes. And this involves IBAGANE, which is

• 1:51:36Andrew D. Huberman?

  Iboga, which is a very long duration psychedelic, 22 hours or more, followed by a, I think, one or two doses of DMT. This is for veterans with, to deal with any number of issues. Appears to be working with great success, and I've spoken to several people who've gone through this. And the way that they described DMT, almost across the board, was, quote, here, I'm just pulling quotes, right, anecdotal, "The most profound experience of my entire life, even greater than the birth of my children." Quote, "Like being attached to the shockwave of an atom bomb." Quote, "There's no way I would do another dose because the first one was so unbelievable."

• 1:52:20Andrew D. Huberman?

  Interesting, by the way. I think most of us, including me, would think, "Why wouldn't you want to do it again, then?" But this idea that that was just beyond anything. So, these are significant, excuse me, these are significant statements, coming from individuals who have existed at the extremes of human experience to begin with, right? These are so-called Tier One operators within the special operations who exit and may or may not have trauma. But DMT sounds like a big deal.

• 1:52:50Speaker 05

  Yeah.

• 1:52:50Andrew D. Huberman?

  Short duration, really big deal. What do we know about its chemistry? What do we know about how it's impacting brain networks? And what in the world is going on that people are describing it as the ways I just mentioned a few moments ago?

• 1:53:05Speaker 05

  Yeah, it's a rocket ship. If, if the salicybin is like a ship leaving port, then yeah, this is, this is a rocket ship into... craziness.

• 1:53:18Andrew D. Huberman?

  Is it five eight, is it serotonin two A?

• 1:53:21Speaker 05

  It it is, yeah. So it is a classic psychedelic. It's a direct agonist, a direct stimulator of the serotonin two A receptor. It's a an order of magnitude less potent than psilocybin. But potency is a funny thing because it's dose dependent. So that doesn't mean that the experience with D M T is less than that of psilocybin. It's just that you give more of the drug. Um, uh, but it has, that's matched by its its stickiness for the serotonin two A receptor, which is this kind of golden rule in in psychedelic sciences that it was discovered in the mid nineteen eighties, this tight relationship between the affinity or the stickiness or the binding potential

• 1:54:05Speaker 05

  of a psychedelic for the two A receptor in particular, serotonin two A, and its potency. And the stickier the drug, the more potent. So L S D really sticky, very, very potent. You only need those tiny microgram doses. So D M T by its affinity is is um a little less potent, but by its effects, when you give a standard dose, it's just in, it's it's just wild. And D M T, because there's another compound called five methoxy D M T, which is a bit different pharmacologically and subjectively. It's it similar in terms of its kinetics. It's another rocket ship.

• 1:54:46Speaker 05

  Um, both compounds um in the wild, so to speak, are um smoked often. D M T and five M E O, people are vaping both actually now. Um, there are vape vape pens that have been uh developed uh for people to administer administer this, but more traditionally, it's been a smoking thing.

• 1:55:11Andrew D. Huberman?

  This is clinically, not recreationally, or both?

• 1:55:14Speaker 05

  Both now. I mean, you know, underground practitioners are using the vape pens. They like them because people titrate the dosage. They get a feel for what it is to be going into this state so that they feel they can let go and go into it. But um. And actually, I think some of the veterans' work might be giving five M E O after the Iber gain. Phenomenologically, if there's a difference between D N T and five M E O, people might put it on five M E O being more of a reliable ego dissolution experience,

• 1:55:51Speaker 05

  less visual and more kind of all round immersion in the greater whole, loss of self-identity and just immersion in everything.

• 1:56:02Andrew D. Huberman?

  Yeah, maybe we could just talk about ego dissolution for a second because it's such a sticky, interesting idea. I can take a step back as a neuroscientist and say, okay, ego dissolution, this idea that, you know, from a very early age, we have a concept of self and that, you know, I wake up every morning and I know I'm me and not somebody else and presumably you do the same and most, most people do the same, I would hope, but that, and that there are objects in the world and people in the world beyond us. But every time I hear about ego dissolution, it sounds like it's a kind of a temporary elimination of the, of the idea that things stop and start and stop between us and everything

• 1:56:46Andrew D. Huberman?

  else. Almost like, you know, in a kind of a, here, I'm not trying to sound philosophical or metaphysical, but there's sort of the molecular continuity of, of life, right? Or all, all just little, little bits.

• 1:56:58Speaker 05

  Which is true.

• 1:56:59Andrew D. Huberman?

  Which is true, right? Not a functional way to go through the day, right? Because you want to make a cup of coffee. You don't really want to get lost in that if your goal is to make a cup of coffee. But, but, you know, what is the, what is the power of ego dissolution? Is it the idea that we, that we like belong? Is it a sense of meaning? Is it the sense that we're, we're not as important as we think, which of course could be a wonderfully useful way to go through life, you know, to, to think that we're not as, as, like, we are vitally important, but we're not the only thing, right? Because I do believe connection is vital, as most people do. What is ego dissolution? And why

• 1:57:42Andrew D. Huberman?

  would this serotonin two A activation cause that? That's remarkable.

• 1:57:48Speaker 05

  Yeah. Great questions. I mean, what, what is it?

• 1:57:54Speaker 05

  You alluded to it with the start stop, I think, you know, because you could define it by boundaries in a sense. What it, what isn't me is as valid here as, as the, you know, a developing sense of what is me that a child develops at whatever age.

• 1:58:15Speaker 05

  And so a major characteristic of the ego dissolution experience, rather than just a negative, a thing going away, my sense of self going away, is, is the positive. Oh, now I feel interconnected with other people and the world at large. And I realize, you know, that there is that molecular continuity. And actually, that's a ground truth. And, or maybe the ego thing is somewhat illusory, or at least the construction of my mind.

• 1:58:47Andrew D. Huberman?

  And indeed it is, right?

• 1:58:48Speaker 05

  Well, it is. Yeah, I mean, there's no transcendentalism about that. It's just like logic.

• 1:58:56Andrew D. Huberman?

  I think about, about it a little bit like family. I mean, we all know what immediate family is, but you know, sort of like, forgive me for interrupting myself. I do it all the time anyway.

• 1:59:06Andrew D. Huberman?

  When I teach neuroanatomy, you know, some clever student always figures out, okay, well, that's connected to that and that's connected. But ultimately, everything in the brain is connected to everything else.

• 1:59:15Speaker 05

  Yeah.

• 1:59:16Andrew D. Huberman?

  There's just no way around that. That's a true statement.

• 1:59:18Speaker 05

  Yeah.

• 1:59:19Andrew D. Huberman?

  And so you really just have to decide where you draw the boundaries between.

• 1:59:23Speaker 05

  Where do you draw the line?

• 1:59:24Andrew D. Huberman?

  Where, what, where are the modules? What are the modules? You could say the brain is just one big macro module.

• 1:59:29Speaker 05

  Yeah.

• 1:59:29Andrew D. Huberman?

  And then you also want to include the body. And now fortunately, people are starting to embrace this idea that it's not mind, body. It's both because the nervous system extends through both, of course. So as, the same could be said of family. Like, we're related, right? Not just by virtue of the fact that we're human beings. If we did our genealogical charts, we would find a convergence at some point.

• 1:59:51Speaker 05

  Yeah.

• 1:59:52Andrew D. Huberman?

  And of course, you know, this becomes a bit of a game. But then one realizes that where you draw the boundaries, and if you draw them at brother, sister, parents, biological parents, et cetera, that's a game too. And so it is just a construct.

• 2:00:09Speaker 05

  Yeah, I mean, it is a fun game, you know, where do you draw the line and when to pass and when to collapse? It's also a classic consideration in science, when to pass.

• 2:00:20Andrew D. Huberman?

  The lumber versus the splitter.

• 2:00:21Speaker 05

  There you go, it's brilliant. Yeah, but you ask this question like, well, why do psychedelics do it? And there we think psychedelics do it because the target receptors, at least, you know, classic psychedelics do it, and that's important to stress. So MDMA doesn't really do it in the same way, might soften the ego a bit, but yeah, that's debatable.

• 2:00:46Andrew D. Huberman?

  My experience with MDMA is that it's such a strong end pathogen.

• 2:00:50Speaker 05

  Yeah.

• 2:00:51Andrew D. Huberman?

  And that it can cause empathy for others.

• 2:00:56Speaker 05

  Yeah.

• 2:00:56Andrew D. Huberman?

  Certainly, you could imagine situations where one in MDMA journey and afterwards says, you know, oh, these, these, my oppressors, you know, are the people that harmed me, they, and here I'm not referring to my experience, but, you know, they did the best with what they have, actually have empathy for them, forgiveness.

• 2:01:13Speaker 05

  Yeah.

• 2:01:13Andrew D. Huberman?

  But also for oneself, that there's an empathy for self, I know I said this earlier, that is very hard for most people to access, perhaps not the narcissists out there listening. They'll be like, of course, empathy for self. But everyone else, I think, all the other healthy people, or the healthy people other than narcissists, and not picking on narcissists, I have to imagine they suffer too. In fact, I think that's the root of their narcissism, that empathy for self is not something that comes reflexively for most people. And here, I'm not talking about self-love or self-respect, but this notion of being able to see the self as not just deserving of love and care, but actually holding that

• 2:01:57Andrew D. Huberman?

  in place while in confrontation with something challenging, in a way that allows more, not less, access to adaptive responses to that challenge. I think that's the way I kind of conceptualize it.

• 2:02:09Speaker 05

  Yeah, yeah. But, I mean, drugs offer a great, they offer great, they are great scientific tools for tackling this question, what is ego dissolution and why do drugs modulate it? And what does that tell you about the brain? You know, because other drugs like cocaine, releasing more of a different neurotransmitter, dopamine. More than serotonin, the opposite is the case with MDMA is more of an ego inflator, right?

• 2:02:38Andrew D. Huberman?

  Oh, absolutely. People become hyperlinear, hyper linked to their own desires and wishes, and future outcomes become an obsession. It's the stuff of kind of American Psycho and the kind of cliches and stereotypes of the eighties cocaine culture.

• 2:02:57Speaker 05

  Yeah, yeah. We did a study once, actually, looking at dose dependent relationship with ego inflation on one axis and ego dissolution on the other, and saw that it just massively passed or differentiated between cocaine and psychedelics. It's quite a neat study.

• 2:03:14Andrew D. Huberman?

  So cocaine makes people's egos super inflated?

• 2:03:17Speaker 05

  Yeah, and doesn't touch dissolution, and the opposite is the case with psychedelics.

• 2:03:22Andrew D. Huberman?

  Is there any neuroimaging to explain how cocaine does that?

• 2:03:26Speaker 05

  That would be a great study. Yeah, great idea.

• 2:03:29Andrew D. Huberman?

  We should do that. I have a sabbatical coming up. I've got 12 months of sabbatical coming up. And I want to, I'm going to show up in your lab.

• 2:03:37Speaker 05

  Yeah, that's a really good one. If it's right to finish the thread on why psychedelics and ego dissolution, we do know some things, or, you know, we have some hypotheses, and it's that the target receptors, the serotonin 2A receptors that classic psychedelics hit, are heavily expressed in what these days I like to call recent brain, because evolutionarily, it's recent brain, it's cortex that humans have more than any other species. If you look at a mapping of cortical expansion from, say, macaque or chimp to human, it's the very same map that you'll find the 2A receptors in. So that's the target. It's, and it's

• 2:04:18Speaker 05

  just easy to think that, oh, well, that could be the egoic brain, you know, and the classic psychedelics come in, they kind of, they scramble up the activity, that's the entropic brain action. And in terms of, you know, the start, stop, the boundaries, that entropic action sort of spreads out the system. It doesn't shut it off, it sort of spreads it out, you know?

• 2:04:46Andrew D. Huberman?

  Dissolution.

• 2:04:47Speaker 05

  Yeah. And, you know, that you were talking about the headspace as well. So that fits, if it's, you know, if it's more capacious, it sort of fits.

• 2:04:59Speaker 05

  The big qualifier with psychedelic therapy that that people rightly bring up is it doesn't last, you know, that's the paradox of it, the paradox of ego dissolution. So the ego might go away during the trip and you have these profound insights about the molecular continuity and how we're all one and interconnected. And then you come down and however long later, you know, the ego comes back, but maybe with a vengeance and sadly, you know, things can go awry when people haven't done the work, perhaps haven't done the integration work and maybe ego defenses come back and, you know, and it's not, it's not a pretty picture.

• 2:05:44Andrew D. Huberman?

  How often do you see that in the trials that you do? What percentage of the, of people coming through, do you think end up with worse than they, they were before the, the trial?

• 2:05:58Speaker 05

  It's very rare in the trials that we've done.

• 2:06:03Speaker 05

  Yeah, but you see defenses come back. So you, you do see people relapse. That's more, you know, if you, if you're pushing out to like three months plus in something like treatment resistant depression, that's more the rule than the exception sadly. People relapse if their histories are, you know, histories of chronic depression, then while you might give them a, a window of wellness, sadly it doesn't last. That's not to say that it, it doesn't ever last, it does. And, and we have people who were in our first treatment resistant depression trial, who are well, to my knowledge today, back at work, doing fantastically well. But sadly, the majority have, have relapsed to my knowledge.

• 2:06:47Andrew D. Huberman?

  And need to do more psychedelic journeys?

• 2:06:50Speaker 05

  Well, they can't because it's illegal. That's been the really difficult situation that we've been up against is that we do a trial where all of a sudden this scheduled one drug becomes a medicine in the trial, or at least an experimental medicine. We give the treatment, it works fantastically well, gives people a remission that they've never really had. For however long and and then the trial ends and they're denied that treatment. And worse still, if they were to have that treatment, they would be committing a crime. It's sort of a sick joke in a way, but that's that's the situation that we've been in.

• 2:07:25Andrew D. Huberman?

  And that's a perfect segue for what I want to talk about now, which is what is the current state of legality in terms of or the progression towards legality? I'd also like to touch on the role of, let's just say, incoming big pharma. There are a lot of startup companies now trying to capitalize on these discoveries that you and others have made.

• 2:07:49Andrew D. Huberman?

  You know, the landscape out there is very unclear to me. Maybe I'll just call out some silos as I see them. And maybe we can draw some bridges between them if they exist. At the ground level, not the grassroots, but at the ground level, I look to laboratories like yours, Matthew Johnson's, Roland Griffiths, some laboratories at Stanford, Nolan Williams, laboratories doing studying the effects of psychedelics in human beings, so not animal models, in terms of their clinical application for the treatment of depression, anorexia, I now know fibromyalgia, trauma, let's lump MDMA in there as well, assuming that it all

• 2:08:34Andrew D. Huberman?

  works in an equivalent way at the level of kind of where the legislature is taking things. Okay, so labs using government money, philanthropy, et cetera. Then there are the the sort of the therapists out there that are accessing what we believe are clean sources of MDMA, psilocybin, LSD to do this. They are doing it illegally. This is in the US or other Western European countries, because obviously it's going to differ by country, who are administering these things sort of on the basis of what they're reading in these studies that you all are publishing, but also expanding on and experimenting hippie flips and combination drugs and ketamine and et cetera.

• 2:09:18Andrew D. Huberman?

  But let's leave ketamine out for right now because it's legal. But there's that. Then there's the, I don't want to say it's sort of recreational slash open market, black market. And here I want to raise a flag to the fact that Dr. Peter Attia did a terrific podcast on this recently in his own podcast, The Drive, the fact that fentanyl, lacing with fentanyl is now showing up in MDMA and psychedelics that are purchased on the street. So, serious caution to those getting it from uncertain sources. And, and then you've got pharma, and then as an umbrella for all of this, you've got the FDA and law enforcement agencies,

• 2:10:01Andrew D. Huberman?

  which currently say this stuff is illegal unless it's being used in a clinical trial. Selling it or possessing it can get you charged with a crime ranging from, I don't want to say because I don't know, but up to felonies, right? Years in prison. Okay. So, can't take it through airports, can't, don't get caught with it, don't buy it, don't sell it, kind of thing. So where are we going from that picture of these silos? I know things are in clinical trials now. Most people, including myself, are not familiar with how the different phases relate to the proximity to legality. Could you just kind of give us the landscape and touch on how long you think it will be before the people that come through your

• 2:10:43Andrew D. Huberman?

  trials could then go get a prescription for psilocybin, or potentially buy it without the risk, from a reliable source, one would hope, but without the risk of getting thrown in jail? I used to live in Oakland, California. My understanding, and please correct me if I'm wrong, folks, don't trust this information, and get in trouble. My understanding is that psilocybin is decriminalized in Oakland, but that's not the same as being legal. So what is going on out there?

• 2:11:11Speaker 05

  Wow, well, so much.

• 2:11:13Andrew D. Huberman?

  Yeah, I just asked 55 questions. But, but feel free to answer just the subside of them if you like.

• 2:11:21Speaker 05

  Oakland's a funny one. I I live close to Oakland. There are head shops in Oakland. Um, you know, um, that might be selling cannabis and and, you know, cannabis-related paraphernalia that are selling mushrooms as well, psilocybin mushrooms.

• 2:11:38Andrew D. Huberman?

  That's a fact.

• 2:11:39Speaker 05

  Openly, yeah.

• 2:11:40Andrew D. Huberman?

  That's a fact. I can I can verify that. I haven't purchased them, but I've gone in and kind of checked it out, like what what's going on here.

• 2:11:46Speaker 05

  Yeah.

• 2:11:47Andrew D. Huberman?

  Yeah.

• 2:11:47Speaker 05

  Yeah, so, you know, uh, the police aren't going to prioritize um that activity, the purchasing of of those mushrooms as a crime now in Oakland because of the decriminalization. So those head shops shouldn't strictly be selling. Well, they shouldn't be selling. Um, they won't have a license to be selling. Licenses don't exist uh yet for that here. Um, but uh let's see whether they get shut down. They probably will. I don't know. But there's a there's a church, you know, in in Oakland that are sort of um say that uh they're they're selling and it's part of sort of religious rites that

• 2:12:33Speaker 05

  they're using that church model as a loophole. Um uh, you know, the way that Native Americans can use peyote and they have a more genuine um a case, I think, because there is a history there. Um, but they're trying to kind of piggyback on that. Anyway, that's that's sort of, you know, close to where we are right now. But um federally, which is really the major inflection point, is the FDA um and the licensing of psychedelics as medicines to be legally prescribed across the country, across the US and beyond. Um, that is close because

• 2:13:13Speaker 05

  the key um phase, so there are different phases of clinical trials, and the key one to know about is phase three. Phase three trials, licensing trials, if they're successful and typically you have to do at least two successful ones, show the results to the regulators who are the FDA, the medicine regulators, and say, is this good enough now for you to give me a license so that I can sell and provide this medicine that we've demonstrated is a medicine? So that work has been done with MDMA therapy for post-traumatic stress disorder, MAPS have led that work and done two phase three trials. I think they've already publicly

• 2:13:56Speaker 05

  announced that the second trial had results consistent with the first. We know the results of the first because they're published and they were remarkably good, something like sixty-seven percent remission rates.

• 2:14:08Andrew D. Huberman?

  And long term, my understanding is some of those remission rates for trauma are years, which is different than what you're describing for psilocybin, where people might need ongoing dosing.

• 2:14:18Speaker 05

  That's true. Yeah, yeah.

• 2:14:21Andrew D. Huberman?

  But of course, just for trauma in those trials. My understanding is those MDMA trials were not focused on depression.

• 2:14:27Speaker 05

  Yes, yes, focused on the trauma. So that's something because that data is being filed now, to my knowledge, like as we speak, and they're anticipating a decision maybe this year with rollout happening as early as next year. I mean, that's sort of best case, I think.

• 2:14:48Andrew D. Huberman?

  Could I ask you, when you say rollout, who's, and it's the appropriate term for MDMA, because of the so-called rolling, about twenty percent of my audience, maybe fifty will understand that not funny joke that I made. Who's going to roll it out? Is this, where would one get the MDMA, the clean source of MDMA, meaning not laced with fentanyl, not laced with methamphetamine, not undergone any chemical conversion to some other drug, which can happen with extended shelf life, et cetera? Are people going to go to their psychiatrist to get MDMA? And who's going to be providing it? Is it going to be some

• 2:15:29Andrew D. Huberman?

  big major pharma? This seems like a serious set of issues.

• 2:15:34Speaker 05

  It is, and I don't have all the answers. I do know that MAPS would be providing because they've done the work and they have set themselves up in a sense. To potentially become the provider, whether as a pharma company, which is the big question they're wrestling with at the moment, it's very expensive to become a pharma company.

• 2:15:59Andrew D. Huberman?

  And yet, they probably deserve to make the choice because they put in so many years of hard work when all of this stuff was considered like raver, culture, party, drug, they were the ones that spotted the therapeutic potential. I mean, we knew there was therapeutic potential based on work going back many decades, but points to them, and I think, I think, in my opinion, they should have the agency to make those decisions.

• 2:16:23Speaker 05

  Yeah, it's a remark, such a remarkable thing that's been achieved, and I, I think they've done it all on philanthropic donations. I think so. Yeah, so there, there is this, yeah, big question mark, and the FDA are also asking questions about, to, to your question, you know, who, who can provide this? Because in the phase three work and up until this point, there's been a MAPS training, a MAPS therapist training, and you have to do this formal training in order to, to be a practitioner within the trials.

• 2:17:03Speaker 05

  But now there's a question from the FDA, whether that MAPS training can be the training that a clinician has to have to now be a provider. And when I say rollout, it's like offering this as a service, essentially. And so where would the referral come from? That's a good question that I'm not hundred percent on the answer, whether it would have to come from a psychiatrist, or whether someone's sort of general physician could do that referral. But they will be going to a provider who is licensed and certified and will have done some training. And there will be a consensus on, you know, what constitutes

• 2:17:47Speaker 05

  good enough training to provide. There will also be some stipulations on the basic underlying professionalism of the clinician who provides. So I imagine there'll have to be a mental health professional. I don't think they would have to necessarily be a psychiatrist. They could be a, I think, a clinical psychologist. For all the dosings, I think. Without question, there would have to be a physician present, or at least within ready access in case of an emergency.

• 2:18:18Andrew D. Huberman?

  Yeah, especially with MDMA because of the propensity for cardiac issues.

• 2:18:22Speaker 05

  Yeah.

• 2:18:22Andrew D. Huberman?

  Because of the amphetamine properties. And where is psilocybin in terms of the phase trials? Is it in phase two, phase three?

• 2:18:31Speaker 05

  It's in phase three. There's psilocybin therapy work being done for treatment-resistant depression by a company called Compass. Those trials, which are always multi-site, so there's always a bunch of teams or labs, in a sense, geographically spread out, that are each contributing to data that then gets massed together and is then submitted as part of the phase three trial results. So that's happening with Compass right now. It's psilocybin therapy for treatment-resistant depression. Those trials have just started and I think the earliest estimate that I heard in a journalistic

• 2:19:12Speaker 05

  article was, because I don't think Compass would say, or they wouldn't say publicly, something like 2026.

• 2:19:19Andrew D. Huberman?

  Twenty-six, wow, so MDMA is ahead of psilocybin.

• 2:19:24Speaker 05

  Yeah, it's quite a few years ahead. And it's more of a, not a certainty, but it's very, very strong position with MDMA, whereas the work's only just begun with psilocybin in terms of the phase three trials. But then you have this other situation of like, however many psychedelic research centers there are now across the globe.

• 2:19:48Speaker 05

  It was nice to, you know, we had the first one in London in 2019. First one in 2019 is 2023 now, and I don't know how many there are, but so much has happened in such a small space of time.

• 2:20:03Speaker 05

  Yes, but you know, all these different indications I've been able to tell you about anorexia and fibromyalgia syndrome, trying to do a trial with a colleague of mine at UCSF in methamphetamine use disorder. He's got a trial going on in Parkinson's disease and chronic lower back pain and bipolar disorder. I mean, there's so much going on, OCD, almost the full gamut of psychiatric disorders, not schizophrenia, to my knowledge, are being looked at. So there's so much ground, you know, ground swell of activity. And I think these small investigator-led studies, typically they're small because

• 2:20:47Speaker 05

  trials are expensive, are going to be reporting positive results. I know what we're seeing, and it will be, you know, four, let's see now, at least four trials, all with really positive results in very difficult to treat disorders. And that's just us. And I know there's so much elsewhere, addiction disorders as well, you know, Mike Johnson's work, obviously, Michael Bogan shoots. So all this compelling ground swell, it's really something. And yet, you know, the system to really make a big breakthrough in terms of licensing is of course slow. And it's, that can frustrate people, but it has to, it has to be done properly.

• 2:21:32Andrew D. Huberman?

  Yeah, else we revert back to what happened in the seventies, where there was a lot of interest in psychedelics. It's kind of interesting to me, there was a close juxtaposition of meditation and kind of behavioral approaches to self-directed state change and psychedelics. Meditation kind of made it through the hatch. I mean, there were some years where it was considered kind of counterculture, woo, magic carpet, weirdo stuff by Western science. But now, I mean, there are tens of, probably tens of thousands is not an overstatement of quality studies exploring how meditation can provide advantages for the mind and even for mental health.

• 2:22:16Andrew D. Huberman?

  And psychedelics are now catching up, but they used to be close cousins in the, in the cultural framework.

• 2:22:24Andrew D. Huberman?

  But the problem was, I think psychedelics were viewed as making people crazy. And university professors lost their jobs for having discussions like the one that you and I are having right now. And some people went to jail, but mostly people either left academic institutions or lost their jobs. Whereas now, these are, some of the, these studies of the sort that you are doing and that are taking place at Stanford and Hopkins and elsewhere are some of the greatest magnetic pull for philanthropy for universities. Donors are very interested in supporting these sorts of studies because they and their

• 2:23:04Andrew D. Huberman?

  family members and people they know suffer from psychiatric illness for which the current big pharma approaches simply have not worked. So it's sort of interesting to me that what once was seen as kind of poison is now being viewed as a potential therapeutic. It's not just interesting, I think it's, hopefully it speaks to the evolution of the human species. People seem to be becoming more open-minded about becoming more open-minded.

• 2:23:36Speaker 05

  Right, that's a good one. Yeah. And yet, yeah, it's, there's so much that's happening so fast. And there's, you know, there are elements of, it's, it's complexifying the space. There's, there is critique, there's been some bad practice in psychedelic therapy, boundary crossing issues that have caused some scandals.

• 2:24:02Andrew D. Huberman?

  That's too bad.

• 2:24:03Speaker 05

  Isn't it?

• 2:24:04Andrew D. Huberman?

  Yeah, well, you know, I think to the gene therapy, right? It just takes one bad incident. You know, gene therapy was on a fast track three decades ago, and then sadly, a child died in a gene therapy trial. And it's like, shut down gene therapy practically for half a decade, and then it slowly started ratcheting up again. Gene therapy broadly defined, and now we're in the age of, you know, potential directed gene therapy using CRISPR and things of that sort, which makes people, some people cringe and other people very excited. You know, if you have Huntington's in your family, CRISPR is like the most exciting technology ever because you could potentially eliminate it from your family line going forward, of course.

• 2:24:45Speaker 05

  So I I just really hope that we can be balanced as this all plays out because it it could go similar way, given the stigma, given the history that people be very twitchy with with um some isolated incidents um and uh you know, I overgeneralize them perhaps um. In a sense, shining a light on them, I think, is important, that that has happened recently is important because it really drills home how important it is that this work be done right and and what the necessary safeguards and and standards should be um.

• 2:25:26Speaker 05

  Uh, yeah, it won't be, it won't be an easy r- road forwards, but um, but let's hope, you know, we've got to hope that it succeeds because current treatments, you know, people talk about the mental health crisis and to your point earlier about anorexia rates, it's not always actually the case when you look at the um epidemiology, when you look at the data, that you see a big inflection in, you know, diagnoses or cases of psychiatric illness. I would say it's more that the treatments haven't moved, they haven't really progressed, they haven't got any better since the nineteen fifty's more or less, and and new drugs have been more of the same.

• 2:26:11Speaker 05

  So there haven't been any paradigm shifts, and that's why I get a little impassioned when I talk about psychedelic therapy and and that point that this is something different, it's not, you know, a drug every day, it, that system is not cutting it, you know, do we really want to keep on with that system? Uh, sure, you know, not everyone will want to trip, and that will terrify some people so much that they'll just want to be on their Lexapro or or a non psychedelic psychedelic or whatever, and of course, you should be allowed to have those options, of course, and the more options, the better.

• 2:26:49Speaker 05

  Um, but I think there is, it's great value in really understanding what psychedelic therapy is and and and I think when you do, you realize that it is a major paradigm challenge on many levels, and and the fact that it's different might be its its greatest appeal at the moment, I think.

• 2:27:13Andrew D. Huberman?

  Well, I am certainly grateful for your passion for the potential for psychedelics to be added to the array of potential treatments. And I really also appreciate how much you put it in there alongside the other treatments, maybe even in combination with other treatments, as opposed to saying, this is the thing that's gonna cure everything. And yet, the passion that you have for this potential paradigm shift, the one that really appears to be happening at the level of clinical data now, is so important. So I want to extend a voice of gratitude for that and for the work that you're doing. I mean, I've been outside of this field, but as a neuroscientist, I've been paying careful

• 2:27:57Andrew D. Huberman?

  attention to it really for the last five, seven years or so. And it's abundantly clear that it is a small group of individuals who are really thinking in terms of how the system works now and what needs to be done in order to change the system for the better, like yourself, that are really the driving force behind this new movement or paradigm shift that without question is going to lead to improvements in mental health and physical health outcomes. So I just want to say thank you for that. Also, thank you so much for joining us today to share this immense knowledge set about the history of psychedelics, what they are, what they aren't, their clinical applications

• 2:28:41Andrew D. Huberman?

  as seen in your laboratory and other laboratories. I'm sure people already noticed this, but you're incredibly generous in terms of attribution and also in your caution about explaining how some of the results, in particular on anorexia, fibromyalgia, are perhaps preliminary but very exciting. They're not published yet, anyway. We wouldn't call them preliminary. And also for touching on mechanism, that it's not just about people feel better, but pointed to some potential underlying mechanisms in terms of connectivity changes and on and on. So thank you so much for your time today. Thank you for the work that you're doing and thank you for the work that is sure to continue. We will provide links to studies in your laboratory, links to your laboratory, so people

• 2:29:26Andrew D. Huberman?

  can learn more and support in the ways that they deem appropriate for them. But just thank you, thank you, thank you. Such important work you're doing, Robin.

• 2:29:35Speaker 05

  Thank you, Andrew. It's been a pleasure.

• 2:29:37Andrew D. Huberman?

  Thank you for joining me today for my discussion with Dr. Robin Carhart-Harris. I hope you found it to be as informative about the science and clinical uses of psychedelics as I did. If you'd like to learn more about Dr. Carhart-Harris's research, or support that research, or inquire into being a research subject in one of his laboratory studies, please see the links in the show note captions. In addition, please see the links to his Twitter account and other social media accounts, also in the show note captions. Also in the show note captions, you'll find a link to Dr. Carhart-Harris's Twitter account, where he regularly posts about new advances in the field of psychedelic science. If you're learning from and/or enjoying this podcast, please subscribe to our YouTube channel. That's a terrific, zero-cost way to support us.

• 2:30:19Andrew D. Huberman?

  In addition, please subscribe to the podcast on both Spotify and Apple. And on both Spotify and Apple, you can also leave us up to a five-star review. Please also check out the sponsors mentioned at the beginning and throughout today's episode. That's the best way to support this podcast. If you have questions for me, or comments about the podcast, or suggestions about guests you'd like me to include on the Huberman Lab podcast, please put those in the comment section on YouTube. I do read all the comments. Not so much on today's episode, but on many previous episodes of the Huberman Lab podcast, we discuss supplements. While supplements aren't necessary for everybody, many people derive tremendous benefit from them for things like improving sleep, hormone support, as well as focus. The Huberman Lab podcast is proud to have partnered with Momentous Supplements. If you'd like to see the supplements discussed on the Huberman Lab podcast, you can go to

• 2:31:04Andrew D. Huberman?

  livemomentus, spelled O-U-S, so it's livemomentous.com/huberman. If you're not already following me on social media, I am Huberman Lab on all platforms, so that's Facebook, LinkedIn, Twitter, and Instagram. And on all those platforms, I post about science and science-related tools, some of which overlaps with the content of the Huberman Lab podcast, but much of which is distinct from the content on the Huberman Lab podcast. So again, it's Huberman Lab on all social media platforms. If you haven't already subscribed to our Neural Network Newsletter, the Neural Network Newsletter is a monthly newsletter. In which we distill down the essential points of particular podcasts and we list out toolkits such as toolkits for sleep, toolkits for neuroplasticity, toolkits for optimizing dopamine, and on and on, all of which is available at zero cost. You simply

• 2:31:47Andrew D. Huberman?

  go to hubermanlab.com, go to the menu, scroll down to newsletter and supply your email. We do not share your email with anybody. Thank you once again for joining me for today's discussion with Dr. Robin Carhart-Harris. And last, but certainly not least, thank you for your interest in science.